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Abstract: In clinical culture media inoculated with patient samples, selective inhibition of commensal
bacteria is essential for accurate diagnosis and eective treatment, as they can mask the presence of
pathogenic bacteria. The alanine analogue, 1-aminoethyltetrazole was investigated as a potential
alanine racemase inhibitor. For eective uptake and enhanced and selective antibacterial activity,
a library of C-terminal 1-aminoethyltetrazole containing di- and oligopeptides were synthesized
by solid phase peptide coupling techniques. The investigation of the antimicrobial activity of the
synthesised compounds identified several clinically applicable selective inhibitors. These enabled
dierentiation between the closely related bacteria, Salmonella and Escherichia coli, which can be
dicult to discriminate between in a clinical setting. In addition, dierentiation between enterococci
and other Gram-positive cocci was also seen.
Keywords: alanine racemase; 1-aminoethyltetrazole; antibacterial agent; selective inhibition; solid
phase peptide synthesis
1. Introduction
In order to treat bacterial infections eectively, and to avoid promoting the evolution of bacterial
resistance against antibacterial drugs, the correct agents must be used. Therefore, rapid and accurate
detection and identification of pathogenic strains are essential. Chromogenic and fluorogenic culture
media are used routinely in the clinical environment for this purpose [1]. A limitation of such media
occurs due to the presence of additional non-pathogenic bacteria which are commonly found in clinical
samples, the presence of which could produce false signals. One way to overcome this problem is to
add selective antibacterial agents to the medium that can specifically prevent the growth of irrelevant
strains, but allow the pathogen under investigation to grow [2].
Our target was the widely-studied enzyme [3] alanine racemase (AlaR). This enzyme plays a key
role in the biosynthesis of bacterial peptidoglycan through its activity in the racemisation of l-alanine
to d-alanine in bacteria. In the past, several alanine racemase inhibitors have been reported [3,4],
and some have been applied as antimicrobial agents. Examples of these include l,l-alafosfalin (1),
the more active prodrug form of the direct AlaR inhibitor l-fosfalin (2). Figure 1 shows these known
alanine racemase inhibitors, which are structurally similar to the natural substrate.
While l-fosfalin (2) is a good AlaR inhibitor in isolated enzyme studies [5], it does not produce
significant antimicrobial eects when applied to intact bacteria. This is thought to be because it passes
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through the cell membrane in insucient quantities to harm the bacteria. In turn, this is due to the
highly ionised and polar character of this molecule, precluding passive diusion. The more eective
compound alafosfalin (1) contains two parts, the AlaR inhibitor fosfalin and a carrier alanine moiety.
Despite also being highly polar, this molecule eectively inhibits the growth of many intact bacterial
strains. This is because, unlike fosfalin itself, it is able to conscript the dipeptide permease system
to cross the bacterial membrane and, after hydrolysis by an intracellular alanine aminopeptidase,
it liberates fosfalin (2) as the active agent [6].
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Figure 1. Exa ples of the kno n alanine race ase inhibitors, alafosfalin (1) and fosfalin (2).
The cost of producing enantiomerically pure l-fosfalin is high and the antibacterial selectivity of its
derivatives is limited [7]. Due to these factors, there is scope for the development of a new series of AlaR
inhibitors. The tetrazole moiety has been utilised as a bioisostere for carboxylic acids in drugs such as
Losartan, where problems occurred with membrane permeability earlier in the development cycle [8].
Thus, to see if a tetrazole bioisoteric replacement would produce interesting activity against AlaR in
intact bacteria, l-1-aminoethyltetrazole 4a-L was prepared and studied as an alanine (3) bioisostere
(Figure 2). In addition, oligopeptide derivatives containing a C-terminal l-1-aminoethyltetrazole were
synthesised from this initial material.
.
2. Results and Discussion
2.1. Chemistry
The synthesis of the key molecule l-1-aminoethyltetrazole 4a-L has been published by Bavetsias [9].
This synthetic route was followed with minor modifications, producing 4a-L in good overall yield
(71%) (Scheme 1).
Cbz-L-Alanine 5a-L was methylated with methyl iodide in the presence of Cs2CO3 in DMF.
The resulting methyl ester 6a-L was transformed to the analogous amide 7a-L in the presence of 7
M ammonia in methanol by heating at 50 C in a sealed tube. In the following step, the amide 7a-L
was converted to nitrile 8a-L using tosyl chloride in pyridine and DCM. Cbz-l-1-aminoethyltetrazole
9a-L was produced by a cycloaddition of the nitrile moiety with NaN3 in the presence of NH4Cl
in DMF. l-1-Aminoethyltetrazole 4a-L was obtained after removing the Cbz-protecting group by
Pd-catalysed hydrogenation. The d-1-aminoethyltetrazole 4a-D and l-1-aminopropyltetrazole 4b-L
were synthesized by the same methodology. l-1-Aminopropyltetrazole 5b-L is a homologue that
enabled a preliminary exploration of the steric requirements for tetrazole based inhibitors of AlaR.
The justification for this is that (1-amino-2-propenyl)phosphonic acid is an inhibitor of AlaR, [10] which
is the comparable homologue of the AlaR inhibitor fosfalin 2.
A series of di- and oligopeptides containing C-terminal l-1-aminoethyltetrazoles were prepared by
a solid phase synthetic approach. The tetrazole moiety has been successfully attached to and removed
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from dierent resins by several research groups [11–14], although to the best of our knowledge its
application in peptide chemistry has never been reported. After careful consideration, 2-chlorotrityl
chloride resin and the matching Fmoc approach were employed due to the mild cleavage conditions
associated with this resin.Molecules 2020, 25, x FOR PEER REVIEW 3 of 26 
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Fmoc-l-1-aminoethyltetrazole 10a-L was prepared by protecting l-1-aminoethyltetrazole 4a-L
with Fmoc chloride in the presence of Na2CO3 [15], and then attached to the 2-chlorotrityl chloride
resin (Scheme 2) [16]. In our optimised method, the resin was not loaded with an excess amount of the
C-terminal unit, which in our case was Fmoc-1-aminoethyltetrazole 10, as is commonly encountered in
general practice. The synthetic procedure with fully loaded resin resulted in the isolation of Fmoc
peptides as minor impurities at the end, resulting in the requirement for further purification steps.
Instead, when loading with a theoretically equivalent ratio, reasonable yields were obtained after
cleavage of the peptides (50–70%) free from the Fmoc peptide impurities that were encountered with a
fully saturated resin, Table 1. The resin bound d-isomer 4a-D and l-1-aminopropyltetrazole 4b-L were
prepared by the same method.Molecules 2020, 25, x FOR PEER REVIEW 4 of 26 
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group was coupled with the appropriate Cbz protected amino acid using HBTU and DIPEA in DMF.
The resin-bound dipeptides 12a,b,d–j were cleaved from the resin by a TFA/DCM/triisopropylsilane
(TIS) mixture in the ratio 5:95:1 eq (equivalent with the theoretical loading of the resin) and resulted
in the protected dipeptides 13a,b,d–j in good to excellent yields (Table 1). The Cbz-protecting group
was removed by Pd-catalysed hydrogenation, Scheme 3; the yield of these reactions depended on the
purity of the protected starting compound.Molecules 2020, 25, x FOR PEER REVIEW 5 of 26 
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Table 1. Yields and conditions for Scheme 3: Abbreviations: p: the cleaved mixture was triturated and
washed with petroleum ether 40–60 C before yield and impurity calculation; n.o.: not observed; a: the
loading was possibly inhomogeneous, and might have been washed with an insucient amount of
piperidine in DMF.
Abbreviation
Loading Ratio (Fmoc-
1-aminoethyltetrazole
10: resin)
Theoretical
Yield of 13
(%) p
Percentage of
Fmoc Residue
in 13%
Yield of 14 (%)
14g-L Gly-L-Ala(T) 1:1 59 n.o. 99
14a-LL L-Ala-L-Ala(T) 1:1 58 5 86
14a-LD L-Ala-D-Ala(T) 1:1 89 <1 58
14d-LL -Ala-L-Ala(T) 1:1 67 2 78
14e-LL L-Nor-L-Ala(T) 1:1 51 14a 77
14h-LL L-Leu-L-Ala(T) 2:1 84 6 81
14h-LD L-Leu-D-Ala(T) 1:1 69 <1 53
14i-LL L-Ile-L-Ala(T) 1:1 62 2 86
14f-LL L-Pyr-L-Ala(T) 2:1 89 12 84
14j-LL L-Phe-L-Ala(T) 1:1 79 15a 20
14b-LL L-Ala-L-EtGly(T) 1:1 52 3 86
A tripeptide analogue, l-alanyl-l-alanyl-l-1-aminoethyltetrazole 14-c-LLL was accessed by
coupling the attached l-1-aminoethyltetrazole 15-L with an Fmoc-l-alanine, and then with a
Cbz-l-alanine. Cbz-l-alanyl-l-alanyl-l-1-aminoethyltetrazole 13c-LLL was cleaved from the resin with
a mixture of 5% TFA, 95% DCM, 1 eq TIS. Subsequent Cbz deprotection by catalytic hydrogenation
resulted in l-alanyl-l-alanyl-l-1-aminoethyltetrazole 14c-LLL (Scheme 4).
Molecules 2020, 25, x FOR PEER REVIEW 6 of 26 
Molecules 2020, 25, x; doi: FOR PEER REVIEW www.mdpi.com/journal/molecules 
Table 1. Yields and conditions for Scheme 3: Abbreviations: p: the cleaved ixture was triturated and 
washed with petroleum ether 40–60 °C before yield and impurity calculation; n.o.: not observed; a: 
the loading was possibly inhomogeneous, and might have been washed with an insufficient amount 
of piperidine in DMF. 
 Abbreviation 
Loading Ratio (Fmoc-
1-aminoethyltetrazole 
10: resin) 
Theoretical 
Yield of 13 
(%) p 
Percentage of 
Fmoc Residue 
in 13% 
Yield of 14 
(%) 
14g-L Gly-L-Ala(T) 1:1 59 n.o. 99 
14a-LL L-Ala L-Ala(T) :1 58 5 86 
14a-LD L-Ala-D-Ala(T) 1:1 89 <1 58 
14d-LL β-Ala-L-Ala(T) 1:1 67 2 78 
14e-LL L-Nor-L-Ala(T) 1:1 51 14a 77 
14h-LL L-Leu-L-Ala(T) 2:1 84 6 81 
14h-LD L-Leu-D-Ala(T) 1:1 69 <1 53 
14i-LL L-Ile-L-Ala(T) 1:1 62 2 86 
14f-LL L-Pyr-L-Ala(T) 2:1 89 12 84 
14j-LL L-Phe-L-Ala(T) 1:1 79 15a 20 
14b-LL L-Ala-L-EtGly(T) 1:1 52 3 86 
A tripeptide analogue, L-alanyl-L-alanyl-L-1-aminoethyltetrazole 14-c-LLL was accessed by 
coupling the attached L-1-aminoethyltetrazole 15-L with an Fmoc-L-alanine, and then with a Cbz-L-
alanine. Cbz-L-alanyl-L-alanyl-L-1-aminoethyltetrazole 13c-LLL was cleaved from the resin with a 
mixture of 5% TFA, 95% DCM, 1 eq TIS. Subsequent Cbz deprotection by catalytic hydrogenation 
resulted in L-alanyl-L-alanyl-L-1-aminoethyltetrazole 14c-LLL (Scheme 4). 
 
Scheme 4. Solid phase synthesis of L-alanyl-L-alanyl-L-1-aminoethyltetrazole 14c-LLL. Reagents and 
conditions: (a) piperidine, DMF; (b) HBTU, DIPEA, DMF; (c) Fmoc-L-Alanine; (d) Cbz-L-Alanine; (e) 
5% TFA, 95% DCM, 1 eq TIS; (f) H2, 0.5% Pd/C, MeOH, 3 bar. 
A series of di-, tri- and tetra-peptidyl derivatives of N-terminal succinyl-, C-terminal L-1-
aminoethyltetrazole 16-LL, 17-LLL, 18-LLLL were synthesised by the same strategy. After the 
Scheme 4. Solid phase synthesis of l-alanyl-l- l l-l-1-aminoethyltetrazole 14c-LLL. Reage ts and
conditions: (a) piperidine, DMF; (b) HBTU, DIPEA, DMF; (c) Fmoc-l-Alanine; (d) Cbz-l-Alanine; (e) 5%
TFA, 95% DCM, 1 eq TIS; (f) H2, 0.5% Pd/C, MeOH, 3 bar.
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A series of di-, tri- and tetra-peptidyl derivatives of N-terminal succinyl-, C-terminal
l-1-aminoethyltetrazole 16-LL, 17-LLL, 18-LLLL were synthesised by the same strategy. After the
introduction of the appropriate number of alanine residues (1–3), the peptides were furnished with a
succinyl group using succinic anhydride and DIPEA in DMF. These substrates were intended to target
bacterial elastase enzymes in order to achieve a dierent pattern of selective inhibition. The rationale
behind this lay in the knowledge that succinyl-tripeptides were cleaved from chromogenic peptidase
substrates by Pseudomonas aeruginosa in a previous study [17].
AlthougH-N-Cbz protected peptides were successfully cleaved from the resin by a mixture of 5%
TFA, 95% DCM, 1 eq TIS, with good solubility in the cleavage medium, the succinyl peptides 16-LL,
17-LLL, 18-LLLL were not suciently soluble in this organic solvent mixture. Due to this they were
instead cleaved from the resin by a better solubilising mixture of 95% TFA, 2.5% H2O, 2.5% TIS. This
method was both eective and convenient, due to the lack of a need for a N-terminal protecting group,
Scheme 5.
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2.2. Microbiological Evaluation
All of the synthesised 1-aminoethyltetrazole derivatives were tested against a panel of clinically
relevant pathogenic bacteria to investigate their antibacterial properties. The minimum inhibitory
concentration (MIC) tests were carried out in antagonist-free, blood supplemented agar media
containing the appropriate 1-aminoethyltetrazole compound in dierent concentrations (1-128 mg/L).
l-Alanyl-l-alanyl-l-1-aminoethyltetrazole 14c-LLL and l-alanyl-l-1-aminoethyltetrazole 14a-LL have
been synthesized and tested against a selected group of bacteria in the past: Escherichia coli, Staphylococcus
aureus and Salmonella enterica serovar Dublin. In this previous work they were reported to be inactive,
which contrasts starkly with the data we report below. However, these dierences in results may be
attributed to dierences in the culture medium that was used, such as peptone content, the specific
bacterial strains studied or even dierences in the inoculum [18,19]. Our more extensive investigation
focused upon clinically relevant strains of pathogenic bacteria, and used protocols that have now been
established as clinical standard over many years.
l-1-Aminoethyltetrazole 4a-L and the d-enantiomer 4a-D displayed no activity when tested at
concentrations of up to 128 mg/L against our panel of clinically relevant bacteria. As already stated,
the natural amino acid alanine is transported as oligopeptide forms into bacterial cells, and not as a
single amino acid [20]. This latest result suggests that the increase in lipophilicity associated with
changing the carboxylate in the natural compound to the tetrazole in our analogue does not produce
eective passive diusion at an extent that would lead to significant antimicrobial activity. Furthermore,
l-1-aminopropyltetrazole 4b-L was also inactive when exposed to the bacteria as the single amino
acid analogue.
In marked contrast to the results with the single amino acid analogues, targeting the dipeptide
permease systems of bacteria proved to be successful and is consistent with the intracellular liberation
of l-1-aminoethyltetrazole 4a-L (Table 2). Depending upon the N-terminal amino acid, the growth of
dierent Gram-negative and Gram-positive bacteria can be inhibited, thus selectivity can be tuned by
choosing specifiC-Natural N-terminal amino acids within the oligopeptide analogues.
Importantly, it was shown that l,l-alanyl peptide 14a-LL was eective in inhibiting the growth
of many Gram-negative species, but did not display inhibition against Salmonella. This pattern of
activity leads to an obvious and important application for this compound; it could be used in Salmonella
selective media to improve the clinical detection of Salmonella from stool samples, in which overgrowth
by commensal gut bacteria, such as E. coli, is problematic [1].
The glycyl peptide 14g-L was only active against a few species, and even then, only in higher
concentrations. In addition, the -alanyl 14d-L substrate did not show any antibacterial activity.
This compound was aimed at targeting -alanyl aminopeptidase, which only presents in a few bacteria,
most notably Pseudomonas aeruginosa [21], Serratia marcescens and Burkholderia cepacia [22]. This result
suggests that either the side chain or the chirality of the N-terminal amino acid might have an important
role in their transportation. Previously reported corresponding -alanyl derivatives of the AlaR
inhibitor fosfalin and -chloroalanine also had limited activities against bacteria, despite other peptide
derivatives of these compounds being well known eective and selective antibacterial agents [23–25].
The compounds displaying longer, more lipophilic side chains i.e., the peptide analogues
l,l-norvalyl 14e-LL, leucyl 14h-LL, isoleucyl 14i-LL and phenylalanyl 14j-LL displayed enhanced
antibacterial activity against Gram-positive bacteria, and suggest roles as new wide spectrum and
selective antibacterial agents. However, what the current data set does not tell us is why this
enhancement in activity is seen.
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Table 2. MIC values (mg/L) of C-terminal 1-aminoethyltetrazole containing dipeptides 14a,d-j; NCTC: National Collection of Type Cultures, Colindale, UK; ATCC:
American Type Culture Collection, Manassas, United States; NT: not tested; a: inoculum 150000 CFU/spot; b: inoculum 10000 CFU/spot; c: the tested compound was
prepared by solution phase peptide coupling; d: the tested compound was prepared by solid phase peptide coupling.
MIC (mg/L)
14a-LL ac 14a-LD ad 14d-L ac 14e-LL ac 14h-LD ad 14i-LL ad 14f-LL ac 14b-LL ad 14g-L bd 14h-LL bc 14j-LL bd
Gram-negative species Strain code Ala- Ala- -Ala- Nor- Leu- Ile- Pyr- Ala- Gly- Leu- Phe-
Acinetobacter baumannii ATCC 19606 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128
Burkholderia cepacia ATCC 25416 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128  1
Enterobacter cloacae NCTC 11936 1 >128 >128 1 >128 4 >128 8 32 1 8
Escherichia coli NCTC 10418 1 >128 >128 1 >128 8 >128 >128 >128 1 4
Klebsiella pneumoniae NCTC 9528 1 >128 >128 1 >128 >128 8 >128 >128 2 16
Providencia rettgeri NCTC 7475 >128 >128 128 >128 >128 >128 >128 >128 >128 >128 >128
Pseudomonas aeruginosa NCTC 10662 64 >128 >128 64 >128 128 >128 >128 >128 64 >128
Salmonella Typhimurium NCTC 74 >128 >128 >128 2 >128 128 >128 >128 >128 64 >128
Serratia marcescens NCTC 10211 2 >128 >128 1 >128 16 8 >128 >128 1 8
Yersinia enterocolitica NCTC 11176 1 >128 >128 1 >128 2 4 >128 128 1 NT
Escherichia coli NCTC 12241 1 >128 >128 1 >128 2 >128 >128 64 1 4
Salmonella Enteritidis NCTC 6676 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128
Gram-positive species
Enterococcus faecalis NCTC 775 >128 >128 >128 1 >128 > 128 2 >128 >128 2 2
Enterococcus faecium NCTC 7171 >128 >128 >128 2 >128 64 2 >128 >128 16 32
Listeria monocytogenes NCTC 11994 >128 >128 >128 4 >128 >128 >128 >128 >128 >128 >128
Staphylococci epidermidis NCTC 11047 > 128 >128 >128 2 >128 >128 >128 >128 >128 2 >128
Staphylococcus aureus NCTC 6571 >128 >128 64 4 128 128 >128 >128 64 16 1
Staphylococcus aureus
(MRSA) NCTC 11939 >128 >128 128 >128 >128 >128 >128 >128 >128 8 >128
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One possibility is that activity against Gram-positive bacteria may occur due to the further
lipophilicity associated with the side chains of this group of substrates. This increased lipophilicity
could promote passive diusion as well as, or instead of, active transport into bacteria. Alternatively,
the enhanced activity of the peptides displaying longer side chains is consistent with the reported
increased anity for large lipophilic side chains with bacterial proton-dependent oligopeptide
transporter proteins [26]. As l,l-leucyl 14h-LL, isoleucyl 14i-LL and phenylalanyl 14j-LL peptides
selectively allow the growth of Salmonella species in low concentrations, they also have potential use
in a new improved Salmonella selective medium. Another useful finding present within the data is
the selective inhibition of enterococci by l-pyroglutamyl derivative 14f-LL [27]. This pyroglutamyl
derivative was selected and synthesized to target enterococci, as they are known to produce an active
pyroglutamyl aminopeptidase enzyme [28]. The great selectivity displayed by this compound could
be attributed to the amide motif on the N-terminus, as the N-terminal amino group is necessary for the
transport carried out by permease systems [20]. Interestingly, the d-1-aminoethyltetrazole containing
peptides 14a-LD, 14h-LD were totally inactive, although their l-1-aminoethyltetrazole containing
diastereomers 14a-LL, 14h-LL inhibited many dierent species (Table 3). This again suggests an active
transport mode of entry wherein the transporter would potentially display chiral selectivity.
Table 3. MIC values of C-terminal 1-aminoethyltetrazole containing oligopeptides; NT: not tested;
a: inoculum 150000 CFU/spot; b: inoculum 10000 CFU/spot.
MIC (mg/L)
18-LLLL a 14c-LLL b 16-LL b 17-LLL b
Gram-negative species Strain code Succ-Ala-)3 Ala-Ala- Succ-Ala- Succ-(Ala-)2
Acinetobacter baumannii ATCC 19606 >128 >128 >128 >128
Burkholderia cepacia ATCC 25416 >128 >128 >128 >128
Enterobacter cloacae NCTC 11936 128 1 >128 >128
Escherichia coli NCTC 10418 >128 2 >128 >128
Klebsiella pneumoniae NCTC 9528 >128 2 >128 >128
Providencia rettgeri NCTC 7475 >128 >128 >128 >128
Pseudomonas aeruginosa NCTC 10662 >128 32 >128 >128
Salmonella Typhimurium NCTC 74 >128 >128 >128 >128
Serratia marcescens NCTC 10211 >128 1 >128 >128
Yersinia enterocolitica NCTC 11176 >128 >128 NT NT
Escherichia coli NCTC 12241 >128 2 >128 >128
Salmonella Enteritidis NCTC 6676 >128 >128 >128 >128
Gram-positive species
Enterococcus faecalis NCTC 775 >128 >128 >128 >128
Enterococcus faecium NCTC 7171 >128 >128 >128 >128
Listeria monocytogenes NCTC 11994 >128 >128 >128 >128
Staphylococci epidermidis NCTC 11047 >128 32 >128 >128
Staphylococcus aureus NCTC 6571 >128 >128 1 2
Staphylococcus aureus
(MRSA) NCTC 11939 >128 >128 >128 >128
l-Alanyl-l-1-aminopropyltetrazole 14b-LL was found to only inhibit Enterobacter cloacae,
among the panel of bacteria that were tested. The contrast between the results obtained with
l-alanyl-l-1-aminopropyltetrazole 14b-LL and l-alanyl-l-1-aminoethyltetrazole 14a-LL represents the
dierence between l-1-aminoethyltetrazole 4a-L and l-1-aminopropyltetrazole 4b-L homologues,
as l-1-aminoethyltetrazole 4a-L displays a bioisosteric replacement of the natural substrate of
AlaR and can inhibit the enzyme in dierent species. The larger homologue 4b-L probably has
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limited access to the active site of the enzyme in most bacterial AlaRThe tripeptide analogue
l-Alanyl-l-alanyl-l-1-aminoethyltetrazole 14c-LLL displayed a similar profile to the previously
discussed dipeptides 14a-LL and 14h-LL, which also suggests potential in media where Salmonella
detection is required. The N-terminal succinyl containing peptides 16-LL, 17-LLL and 18-LLLL did
not produce significant inhibitory eects against most bacteria, Table 3.
3. Materials and Methods
3.1. General Information
All commercially available reagents and solvents were obtained from Sigma-Aldrich Dorset, UK),
Apollo Scientific (Stockport, UK), Alfa Aesar (Heysham, UK), Fluorochem (Glossop, UK), or Fischer
Scientific (Loughborough, UK) and were used without further purification. Melting points were
recorded on a Reichart-Kofler hot-stage microscope apparatus (Reichart, Vienna, Austria) and are
uncorrected. Infrared spectra were recorded in the range 4000–600 cm 1 using a Spectrum BX FT-IR
spectrophotometer (Perkin Elmer, Beaconsfield, UK). NMR spectra were obtained using an Ultrashield
300 spectrometer (Bruker, Coventry, UK) at 300 MHz for 1H spectra or at 75 MHz for 13C spectra
and a Bruker Avance III Ultrashield spectrometer at 500 MHz for 1H spectra or at 125 MHz for
13C spectra. Low-resolution mass spectra were recorded on a Bruker Esquire 3000plus analyser
using an electrospray source in either positive or negative ion mode. High resolution accurate mass
measurements were collected by the EPSRC-National Mass Spectrometry Facility at Swansea University.
Elemental analyses were performed using an CE-440 Elemental Analyzer (Exeter Analytical, Coventry,
UK). Thin layer chromatography was performed on silica gel 60F254 (Merck, Hoddesdon, UK). Thin
layer chromatography results were analysed by UV lamp (254 nm), ninhydrin stain (amine, amide
content) and/or ceric ammonium molybdate stain (oxidising agent). Fischer silica gel 60 (35-70 micron,
Fischer Scientific, Loughborough, UK) was used for column chromatography; the samples were
pre-absorbed onto silica 60 (35-70 micron). LC-MS analysis was performed using a 1290 Infinity
Series HPLC system (Agilent, Waldbronn, Germany) and an Agilent 6120 Quadrupole LC-MS detector.
LC-MS data was analysed by an Agilent ChemStation. Where required, compounds were purified
by Agilent 1260 preparative HPLC. Hydrogenation reactions were performed in a Parr 4560 mini
benchtop reactor (SciMed, Stockport, UK). Air and moisture sensitive reactions were carried out in
oven dried glassware under a nitrogen atmosphere.
3.2. Chemistry
3.2.1. General Method A: Synthesis of Protected Amino Acid Methyl Ester:
To a solution of N-protected-amino acid (26.4 mmol) in dry DMF (70 mL) caesium carbonate
(4.72 g, 14.5 mmol) was added and the mixture was stirred for 30 min at room temperature. After
dropwise addition of methyl iodide (1.73 mL, 27.8 mmol), the reaction was stirred overnight. Ethyl
acetate (50 mL) was then added to the mixture and it was washed with water (3  50 mL), then the
combined aqueous phase was extracted with ethyl acetate (50 mL). The combined organic phase
was washed with 10% K2CO3 solution (2  30 mL), then with brine (30 mL), dried over MgSO4,
and subsequently filtered. The solvent was removed under reduced pressure to give the product as a
white solid.
3.2.2. General Method B: Synthesis of Protected Amino Amides:
The protected amino acid methyl ester (420 mmol) was dissolved and stirred in 7 M solution of
ammonia in methanol (60 mL) overnight at 50 C in a sealed tube. After the reaction was complete,
as determined by TLC, the mixture was evaporated to dryness under reduced pressure.
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3.2.3. General Method C: Synthesis of Protected Amino Nitrile:
To a solution of the required N-protected-alanineamide (19.0 mmol) in DCM (9 mL), pyridine
(14 mL) was added. After cooling to 0 C, tosyl chloride (4.7 g, 24.7 mmol) was added to the solution.
Stirring was continued for 30 min at 0 C and then overnight at room temperature. After the reaction as
complete, as determined by TLC, the system was cooled to 0 C and quenched with water (70 mL) nd
ethyl acetate (70 mL). After separation, the aqueous layer was extracted with ethyl acetate (4  30 mL)
and the combined organic phase was washed with 1.2 M HCl (3  40 mL), and saturated NaHCO3
(50 mL), then brine (50 mL). The whole solution was dried over MgSO4, and evaporated under
reduced pressure.
3.2.4. General Method D: Synthesis of Cbz-1-Aminoalkyltetrazole:
To a suspension of NH4Cl (2.03 g, 38 mmol) and NaN3 (2.62 g, 38 mmol) in dry DMF (60 mL)
in a two-necked round bottom flask equipped with reflux condenser and drying tube, the required
Cbz-amino nitrile (38 mmol) was added. The mixture was stirred and heated to 90 C for 1 h. To the
cooled mixture, another portion of NH4Cl (1.04 g, 19 mmol) and NaN3 (1.31 g, 19 mmol) were added
and the mixture was heated at 90 C overnight. When the reaction was complete, as determined
by TLC, the mixture was filtered and the residue was washed with ethyl acetate. The filtrate was
evaporated under reduced pressure. Water (180 mL) was added to the residue and it was acidified to
pH 1 with 2.5 M HCl aqueous solution. The precipitated solid was filtered o and washed with water
to give the product.
3.2.5. General Method E: Removal of the Cbz Protecting Group:
To the solution of the protected amino acid or peptide derivative (1.0 meq) in methanol,
5% palladium on activated carbon (0.1 meq) was added portion wise. The mixture was stirred
at room temperature under 2 bar pressure of hydrogen overnight in an autoclave. After the reaction
was complete determined by TLC, the mixture was filtered through celite and then the solvent removed
in vacuum.
3.2.6. General Method F: Fmoc Protection:
10% Aqueous Na2CO3 (13 mL) was added to the suspension of 1-aminolakyltetrazole (4.87 mmol)
in 1,4-dioxane (7 mL). After the addition of Fmoc chloride (1.38 g, 5.35 mmol) solution in 1,4-dioxane
(7 mL), the mixture was stirred for 30 min at 0 C, then overnight at room temperature. When the
reaction was complete, as determined by TLC, it was acidified with 2.5 M HCl aqueous solution
(11 mL). The mixture was filtered and the solid product was washed with water before drying.
3.2.7. General Method G: Solid Phase Peptide Coupling:
Swelling: The resin was bubbled for 30 min in a long-necked glass sinter in a solvent (DMF or
DCM) with a volume 3x that of the bed volume. Subsequently the solvent was removed by filtration.
Washing o: The resin was washed with DMF (3  8 mL for 30 s), IPA (2  8 mL for 30 s) and
finally with petroleum ether (40–60 C) (2  8 mL for 30 s). The resin was air-dried, then dried in a
vacuum oven at 40 C overnight. The solvents were removed by filtration after each step.
Attachment to 2-chlorotrityl chloride resin: After swelling the resin in DCM the solution of
Fmoc-1-aminoalkyltetrazole 4 and DIPEA in DCM was added to the resin, and the mixture was bubbled
for 2 h. After filtration, the resin was bubbled with DCM, DIPEA and methanol mixture for 1 h. Later
the resin was washed with DMF (3  8 mL for 30 s), methanol (3  8 mL for 30 s) then with DCM or
petroleum ether (40–60 C) (3  8 mL for 30 s) depending on whether the resin needed to be swelled or
dried. The solvents and solutions were removed by filtration after each step.
Fmoc deprotection: The resin swelled in DMF was treated with a mixture of piperidine and DMF
(1:4 ratio, 10 mL/g resin, 1  5 min and 3  10 min), then it was alternately washed with DMF and IPA
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(2  8 mL for 30 s) finished with washing with DMF (8 mL for 30 s). The solvents and solutions were
removed by filtration after each step.
Fmoc test: A sample consisting of a few resin beads was washed with DMF (4  1 mL for 30 s),
IPA (5  1 mL for 30 s) and with methanol (2  1 mL for 30 s), followed by transfer into a separate flask
by washing with 1% TFA in DCM (2  1 mL for 30 s). The filtrate was placed on a TLC plate with a
capillary and observed under UV light (254 nm). A positive test shows fluorescence on the TLC plate.
The solvents and solutions were removed by filtration after each step.
Coupling: DIPEA (1 eq) was added to the solution of HBTU (3 eq) and the protected amino acid
(3 eq) in DMF (10 mL). The solution was stirred for 8 min and then it was added to the swelled resins.
After 20 min bubbling witH-Nitrogen, more DIPEA (0.5 eq) was added to the mixture, then it was
bubbled until the TNBS test showed a negative result. After the reaction was complete the resin was
washed o using the procedure mentioned above.
Coupling with succinic anhydride: The solution of succinic anhydride (3 eq) in DMF (10 mL) was
added to the swelled resins, followed by the addition of DIPEA (1 eq). It was bubbled until the TNBS
test showed a negative result (typically 1 h). After the reaction was over the resin was washed o using
the procedure mentioned above.
TNBS test: The solution of DIPEA in DMF (10%, 3 drops) and the aqueous solution of TNBS (1 M,
3 drops) were mixed with sample consisting of a few resin beads. After a waiting period of 10 min,
the resin beads were inspected under a light microscope (magnification 4). The result was positive if
the beads were coloured red, orange or yellow and it was negative if the beads were colourless.
Cleavage from resin: The resin swelled in DCM was treated with 1% TIS containing TFA, DMF
mixture (5:95 ratio, 10 mL/g) for 1 h. After washing the resin with the same TFA, DCM mixture,
the filtrate was evaporated under reduced pressure. (Supplementary Materials).
HPLC method A: column: ACE 5 C18 (150  3 mm i.d.); eluent: isocratic: water (0.1% formic acid)
- methanol (0.1% formic acid) 95:5 ratio. The purity of all the compounds tested using this method
were 95%.
HPLC method B: column: ACE 5 C18 (150  3 mm i.d.); eluent: isocratic: water (0.1% formic acid)
- methanol (0.1% formic acid) 80:20 ratio. The purity of all the compounds tested using this method
were 95%.
HPLC method C: column: ACE 5 C18 (150  3 mm i.d.); eluent: isocratic: water (0.1% formic acid)
- methanol (0.1% formic acid) 50:50 ratio. The purity of all the compounds tested using this method
were 95%.
HPLC method D: column: ACE 5 C18 (150  3 mm i.d.); eluent: isocratic: water (0.1% formic acid)
- methanol (0.1% formic acid) 20:80 ratio. The purity of all the compounds tested using this method
were 95%.
Prep HPLC method A: column: Vydac protein and peptide 218TP510; eluent: gradient: water
(0.1% formic acid) - methanol (0.1% formic acid) (0–90%).
Methyl-(2S or R)-2-{[(benzyloxy)carbonyl]amino}propanoate (6a) [29]: Cbz-l/d-alanine 5a (10.0 g, 45.0 mmol)
was esterified and worked up using general method A, yielding the desired product as a white powder
(10.6 g, 99%). The reaction and the work up were monitored by TLC (eluent: petroleum ether (40–60 C)
- ethyl acetate, 2:1 ratio, Rf: 0.51). Mp: 41–43 C (literature: 43–44 C, light petrol)[30]; 1H-NMR
(300 MHz, DMSO-d6) H 7.74 (1H, d, J = 7.5 Hz, 5-H), 7.34 (5H, m, 9,10,11-H), 5.03 (2H, s, 7-H), 4.11 (1H,
quint, J = 7.5 Hz, 2-H), 3.63 (3H, s, 4-H), 1.27 (3H, d, J = 7.2 Hz, 3-H); 13C-NMR (75.5 MHz, DMSO-d6)
C 173.8 (1-C), 156.3 (6-C), 137.4 (8-C), 128.8 (2C, 10-C), 128.3 (11-C), 128.2 (2C, 9-C), 65.9 (7-C), 52.3
(4-C), 49.8 (2-C), 17.4 (3-C); max/cm 1 3335 (N-H), 1703 (C=O), 1668 (C=O), 1524 (N-H), 1209 (C-O);
MS(ESI) m/z 260.1 (M + Na)+.
Benzyl-N-[(1S or R)-1-carbamoylethyl]carbamate (7a) [9]: Cbz-l/d-alanine methyl ester 6a (10.0 g, 42 mmol)
was reacted and worked up using general method B, to give the product as a white powder (9.40 g,
99%). The reaction and the work up were monitored by TLC (eluent: petroleum ether (40–60 C) -
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ethyl acetate, 1:1 ratio, Rf: 0.11). Mp: 131–132 C (literature: 130–131 C, methanol–diethyl ether)[31];
1H-NMR (300 MHz, DMSO-d6) H 7.35 (6H, m, 5,9,10,11-H), 7.26 (1H, s, 4-Ha), 6.93 (1H, s, 4-Hb),
5.02 (2H, s, 7-H), 3.98 (1H, quint, J = 7.2 Hz, 2-H), 1.21 (3H, d, J = 7.2 Hz, 3-H); 13C-NMR (75.5 MHz,
DMSO-d6) C 174.9 (1-C), 156.1 (6-C), 137.5 (8-C), 128.76 (2C, 10-C), 128.2 (11-C), 128.1 (2C, 9-C), 65.8
(7-C), 50.4 (2-C), 18.7 (3-C); max/cm 1 3386 (N-H), 3308 (N-H), 3196 (N-H), 1651 (C=O), 1537 (N-H),
1247 (C-O); MS(ESI) m/z 223.1 (M + H)+.
Benzyl-N-[(1S or R)-1-cyanoethyl]carbamate (8a) [9]: Cbz-l/d-alanine amide 7a (3.48 g, 15.7 mmol) was
reacted and worked up using general method C. The crude product was washed with heptane to
give the product as white crystals (3.12 g, 97%). The reaction and the work up were monitored by
TLC (eluent: petroleum ether (40–60 C) - ethyl acetate 1:1 ratio, Rf: 0.41). Mp: 79–80 C (literature:
82–83 C [32]); 1H-NMR (300 MHz, DMSO-d6) H 8.14 (1H, d, J = 5.4 Hz, 4-H), 7.37 (5H, m, 8,9,10-H),
5.08 (2H, s, 6-H), 4.59 (1H, quint, J = 7.2 Hz, 2-H), 1.43 (3H, d, J = 7.2 Hz, 3-H); 13C-NMR (75.5 MHz,
DMSO-d6) C 155.7 (5-C), 137.0 (7-C), 128.9 (9-C), 128.5 (10-C), 128.4 (8-C), 120.9 (1-C), 66.5 (6-C), 38.2
(2-C), 18.8 (3-C); max/cm 1 3332 (N-H), 2356 (CN), 1686 (C=O), 1521 (N-H), 1253 (C-O); MS(ESI) m/z
227.1 (M + Na)+.
Benzyl-N-[(1S or R)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamate (9a) [9]: Cbz-l/d-alanyl nitrile (8a, 7.80 g,
38.0 mmol) was reacted and worked up using general method D. The product was gained as a white
solid (7.55 g, 80%). The reaction and the work up were monitored by TLC (eluent: petroleum ether
(40–60 C) - ethyl acetate 1:1, Rf: 0.09). Mp: 134–138 C (literature: 139–141 C [33]); 1H-NMR (300 MHz,
DMSO-d6) H 7.99 (1H, d, J = 6.9 Hz, 4-H), 7.33 (5H, m, 9,10,11-H), 5.01 (3H, m, 2,7-H), 1.49 (3H, d,
J = 7,2 Hz, 3-H); 13C-NMR (75.5 MHz, DMSO-d6) C 158.6 (1-C), 155.7 (6-C), 136.8 (8-C), 128.31 (2C,
10-C), 127.8 (3C, 9,11-C), 65.7 (7-C), 41.9 (2-C), 19.3 (3-C); max/cm–1 3308 (N-H), 2980, 2866, 2738, 2614
(tetrazole), 1686 (C=O), 1524 (N-H), 1255 (C-O); MS(ESI) m/z 248.1 (M + H)+.
(1S or R)-1-(1H-1,2,3,4-tetrazol-5-yl)ethan-1-amine (4a) [9]: Cbz-l/d-aminoethyltetrazole (9a, 0.75 g,
3.0 mmol) was deprotected using general method E. Following filtration, the solid residue was washed
with ethanol and the filtrate was evaporated under reduced pressure to give the product as a white
solid (0.33 g, 97%). The reaction and the work up were monitored by TLC (eluent: ethyl acetate -
ethanol 8:1 ratio, Rf: 0.03). Mp: 230 C (decomposed) (literature: 268–270 C, (decomposed) [9]).
1H-NMR (300 MHz, DMSO-d6) H 4.55 (1H, quart, J = 6.6 Hz, 2-H), 1.54 (3H, d, J = 6.9 Hz, 3-H);
13C-NMR (75.5 MHz, DMSO-d6) C 160.4 (1-C), 44.1 (2-C), 19.8 (3-C); max/cm–1 3388 (N-H), 2916, 2719,
2634, 2522 (tetrazole); MS(ESI) m/z 114.1 (M + H)+.
Methyl-(2S)-2-{[(benzyloxy)carbonyl]amino}butanoate (6b-L) [34]: Cbz-l-ethylglycine (5b-L, 5.0 g,
21.0 mmol) was reacted and worked up using general method A, yielding the product as colourless oil
(5.1 g, 97%). The reaction and the work up were monitored by TLC (eluent: petroleum ether (40–60 C)
- ethyl acetate, 2:1 ratio, Rf: 0.77). 1H-NMR (300 MHz, DMSO-d6) H 7.69 (1H, d, J = 7.5 Hz, 6-H), 7.36
(5H, m, 10,11,12-H), 5.04 (2H, s, 8-H), 3.97 (1H, td, J = 5.4, J = 8.4 Hz, 2-H), 3.63 (1H, s, 5-H), 1.66 (2H,
m, 3-H), 0.89 (3H, t, J = 7.2 Hz, 4-H); 13C-NMR (75.5 MHz, DMSO-d6) C 173.2 (1-C), 156.6 (7-C), 137.4
(9-C), 128.8 (11-C), 128.3 (12-C), 128.2 (10-C), 65.9 (8-C), 55.8 (2-C), 52.2 (5-C), 24.6 (3-C), 10.9 (4-C);
max/cm–1 3345 (N-H), 1703 (C=O), 1520 (N-H), 1206 (C-O); MS(ESI) m/z 250.8 (M – H)-.
Benzyl-N-[(1S)-1-carbamoylpropyl]carbamate (7b-L) [35]: Cbz-l-ethylglycine methyl ester (6b-L, 2.0 g,
8.0 mmol) was reacted and worked up using general method B. The crude product was washed
with diethyl ether to give the product as white crystals (1.72 g, 91%). The reaction and the work up
were monitored by TLC (eluent: petroleum ether (40–60 C) - ethyl acetate, 1:1 ratio, Rf: 0.07). Mp:
140–142 C (literature: 141 C [36]); 1H-NMR (300 MHz, DMSO-d6) H 7.36 (5H, m, 10,11,12-H), 7.29
(1H, s, 5a-H), 7.20 (1H, d, J = 8.4 Hz, 6-H), 6.95 (1H, s, 5b-H), 5.03 (2H, s, 8-H), 3.87 (1H, td, J = 5.4, J =
8.4 Hz, 2H), 1.67 (1H, m, 3a-H), 1.55 (1H, m, 3b-H), 0.86 (3H, t, J = 7.2 Hz, 4-H); 13C-NMR (75.5 MHz,
DMSO-d6) C 174. 2 (1-C), 156.4 (7-C), 137.6 (9-C), 128.8 (11-C), 128.2 (12-C), 128.1 (10-C), 65.8 (8-C),
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56.3 (2-C), 25.6 (3-C), 10.8 (4-C); max/cm–1 3380 (N-H), 3308 (N-H), 3196 (N-H), 1649 (C=O), 1535
(N-H), 1240 (C-O); MS(ESI) m/z 237.1 (M + H)+.
Benzyl-N-[(1S)-1-cyanopropyl]carbamate (8b-L) [37]: Cbz-l-ethylglycine amide (7b-L, 4.25 g, 18.0 mmol)
was reacted and worked up using general method C to give the product as white crystals (3.88 g, 99%).
The reaction and the work up were monitored by TLC (eluent: petroleum ether (40–60 C) - ethyl
acetate 1:2 ratio, Rf: 0.64). Mp: 43–45 C; 1H-NMR (300 MHz, DMSO-d6) H 8.15 (1H, d, J = 7.8 Hz,
5-H), 7.37 (5H, m, 9,10,11-H), 5.09 (2H, s, 7-H), 4.48 (1H, quart, J = 7.8 Hz, 2-H), 1.78 (2H, pentd, J = 1.5,
J = 7.5 Hz, 3-H), 0.96 (3H, t, J = 7.2 Hz, 4-H); 13C-NMR (75.5 MHz, DMSO-d6) C 156.0 (6-C), 137.0 (8-C),
128.9 (10-C), 128.5 (11-C), 128.5 (9-C), 120.1 (1-C), 66.6 (7-C), 44.2 (2-C), 25.8 (3-C), 10.3 (4-C); max/cm–1
3312 (N-H), 1694 (C=O), 1524 (N-H), 1263 (C-O); MS(ESI) m/z 219.1 (M + H)+.
Benzyl-N-[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)propyl]carbamate (9b-L) [38]: Cbz-l-ethylglycyl nitrile (8b-L,
3.9 g, 18 mmol) was reacted and worked up using general method D. The product was gained as a
white solid (3.83 g, 81%). The reaction and the work up were monitored by TLC (eluent: petroleum
ether (40–60 C) - ethyl acetate 1:2, Rf: 0.20). Mp: 142–144 C ; 1H-NMR (300 MHz, DMSO-d6) H 7.98
(1H, d, J = 7.2 Hz, 6-H), 7.36 (5H, m, 10,11,12-H), 5.08 (1H, d, J = 12.3 Hz, 8a-H), 5.02 (1H, d, J = 12.6 Hz,
8b-H), 4.83 (1H, quart, J = 8.1 Hz, 2-H), 1.89 (2H, m, 3-H), 0.89 (3H, t, J = 7.2 Hz, 4-H); 13C-NMR
(75.5 MHz, DMSO-d6) C 158.4 (1-C), 156.4 (7-C), 137.3 (9-C), 128.8 (11-C), 128.3 (12-C), 128.2 (10-C),
66.1 (8-C), 48.2 (2-C), 26.7 (3-C), 10.7 (4-C); max/cm–1 3296 (N-H), 2976, 2880, 2714, 2615, (tetrazole),
1686 (C=O), 1528 (N-H), 1263 (C-O); MS(ESI) m/z 262.1 (M + H)+.
(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)propane-1-amine (4b-L) [39]: Cbz-l-aminopropyltetrazole (9b-L, 3.72 g,
14.0 mmol) was deprotected using general method E. Following filtration, the solid residue was washed
with ethanol and the filtrate was evaporated under reduced pressure to give the crude, which was
washed to gain the pure product as a white solid (1.60 g, 88%). The reaction and the work up were
monitored by TLC (eluent: ethanol, Rf: 0.18). Mp: 260 C, decomposed (literature: 273–274 C [39]).
1H-NMR (300 MHz, D2O) H 4.62 (1H, t, J = 7.2 Hz, 2-H), 2.05 (2H, quint, J = 7.5 Hz, 3-H), 0.82 (3H, t,
J = 7.5 Hz, 4-H); 13C-NMR (75.5 MHz, D2O) C 159.6 (1-C), 48.7 (2-C), 26.0 (3-C), 8.9 (4-C); max/cm–1
2820, 2716, 2613, 2561 (tetrazole), 1530 (N-H); MS(ESI) m/z 128.1 (M + H)+.
9H-Fluoren-9-ylmethyl-N-[(1S or R)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamate (10a) [40]: l/d-1-
Aminoethyltetrazole (4a, 2.00 g, 17.7 mmol) was reacted using general method F. The crude product
was purified by recrystallization from acetonitrile to give the pure product as white crystals (0.92 g,
56%). The reaction and the work up was monitored by TLC (eluent: dichloromethane – ethanol 20:1
ratio, Rf: 0.07). Mp: 197–199 C (literature: 200–202 C (decomposed) [40]); 1H-NMR (300 MHz,
DMSO-d6) H 8.05 (1H, d, J = 7.5 Hz, 4-H), 7.88 (2H, d, J = 7.5 Hz, 13-H), 7.71 (2H, t, J = 6.6 Hz, 10-H),
7.41 (2H, t, J = 7.2 Hz, 12-C), 7.31 (2H, m, 11-H), 5.01 (1H, quint, J = 7.2 Hz, 2-H), 4.32 (1H, m, 8-H), 4.24
(2H, m, 7-H), 1.51 (3H, d, J = 6.9 Hz, 3-H); 13C-NMR (75.5 MHz, DMSO-d6) C 159.0 (1-C), 156.0 (6-C),
144.3 (9a-C), 144.2 (9b-C), 141.2 (14-C), 128.1 (12-C), 127.5 (11-C), 125.7 (10-C), 120.6 (13-C), 66.2 (7-C),
47.1 (8-C), 42.3 (2-C), 19.8 (3-C); max/cm–1 3310 (N-H), 2965, 2868, 2740, 2617 (tetrazole), 1686 (C=O),
1523 (N-H), 1258 (C-O); MS(ESI) m/z 336.2 (M + H)+.
9H-Fluoren-9-ylmethyl-N-[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)propyl]carbamate (10b-L): l-1-Amino-ethyltetrazole
(4b-L, 1.79 g, 6.9 mmol) was reacted using general method F. The crude product was purified by
recrystallization in 2 generations from acetonitrile to give the pure product as white crystals (1.66 g, 75%).
The reaction and the work up were monitored by TLC (eluent: dichloromethane – ethanol 10:1 ratio, Rf:
0.21). Mp: 209–211 C (melted and decomposed); 1H-NMR (300 MHz, DMSO-d6) H 16.26 (6-H), 8.04 (1H,
d, J = 7.8 Hz, 5-H), 7.89 (2H, d, J = 7.5 Hz, 14-H), 7.72 (2H, t, J = 7.2 Hz, 11-H), 7.42 (2H, t, J = 7.5 Hz, 13-H),
7.33 (2H, m, 12-H), 4.81 (1H, quart, J = 8.1 Hz, 2-H), 4.34 (2H, m, 8-H), 4.23 (1H, m, 9-H), 1.91 (2H, m, 3-H),
0.88 (3H, t, J = 7.2 Hz, 4-H); 13C-NMR (75.5 MHz, DMSO-d6) C 156.4 (7-C), 144.3 (10a-C), 144.2 (10b-C),
141.2 (15-C), 128.1 (13-C), 127.5 (12-C), 125.7 (11-C), 120.6 (14-C), 66.2 (8-C), 48.1 (2-C), 47.1 (9-C), 26.6 (3-C),
10.7 (4-C); max/cm–1 3300 (N-H), 2978, 2876, 2717, 2617 (tetrazole), 1682 (C=O), 1533 (N-H), 1265 (C-O);
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MS(ESI) m/z 350.1 (M + H)+; CHN [Found: C, 65.08; H, 5.53; N, 19.86. C19H19N5O2 requires C, 65.32; H,
5.48; N, 19.86%].
Benzyl-N-({[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}methyl)carbamate (13g-L): Prepared using
general method G. The Fmoc group of Fmoc-1-l-aminoethyltetrazole attached to 2-chlorotrityl
chloride resin (resin:loading; 1:1 ratio; 1.3 mmol) was removed, this was monitored by the Fmoc and
TNBS tests. After the coupling of Cbz-glycine with the resin, the title compound was cleaved o.
The cleaving mixture (TFA/DCM/TIS, ratio 5:95:1 eq) was removed by evaporation under reduced
pressure. The residue washed with petroleum ether (40 – 60 C) to obtain the product as white crystals
(0.24 g, 59%). The reaction and the work up were monitored by TLC (eluent: ethanol, Rf: 0.56). Mp:
134–136 C; 1H-NMR (300 MHz, DMSO-d6) H 8.56 (1H, d, J = 7.2 Hz, 4-H), 7.35 (6H, m, 7,12,13,14-H),
5.24 (1H, quint, J = 7.2 Hz, 2-H), 5.03 (2H, s, 10-H), 3.68 (2H, d, J = 6.3 Hz, 6-H), 1.49 (3H, d, J = 6.9 Hz,
3-H); 13C-NMR (75.5 MHz, DMSO-d6) C 169.3 (5-C), 158.9 (1-C), 156.9 (9-C), 137.5 (11-C), 128.8 (13-C),
128.2 (14-C), 128.1 (12-C), 65.9 (10-C), 43.8 (6-C), 40.3 (2-C), 19.8 (3-C); max/cm–1 3289 (N-H), 3269
(N-H), 1697 (C=O), 1661 (C=O), 1530 (N-H), 1244 (C-O); MS(ESI) m/z 305.1 (M + H)+; HRMS (Found
(M + H)+ 305.1360. Calcd. for C13H17O3N6: (M + H)+ 305.1357.); (Purity test: HPLC method D).
2-Amino-N-[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]acetamide (14g-L): Cbz-glycyl-1-l-aminoethyl-tetrazole
(13g-L, 0.18 g, 0.57 mmol) was deprotected by general method E. Following filtration, the solid residue
was washed with 30 mL methanol, which was discarded. The solid residue was washed into a separate
flask with water, which was freeze dried to give the product as a white solid (0.01 g, 99%). Further
purification was performed by Prep HPLC method A. Mp: 180 C (decomposed); 1H-NMR (300 MHz,
D2O) H 5.27 (1H, quart, J = 6.9 Hz, 2-H), 3.75 (2H, s, 6-H), 1.52 (3H, d, J = 6.9 Hz, 3-H); 13C-NMR
(75.5 MHz, D2O) C 167.3 (5-C), 164.3 (1-C), 42.3 (2-C), 41.0 (6-C), 19.3 (3-C); max/cm–1 3215 (N-H),
1672 (C=O) 1547 (N-H); MS(ESI) m/z 171.1 (M + H)+; HRMS (Found (M + H)+ 171.0987. Calcd. for
C5H11ON6: (M + H)+ 171.0989.); (Purity test: HPLC method A).
Benzyl-N-[(1S)-1-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}ethyl]carbamate (13a-LL): Prepared
using general method G. The Fmoc group of Fmoc-1-l-aminoethyltetrazole attached to 2-chlorotrityl
chloride resin (resin:loading; 1:1 ratio; 1.3 mmol) was removed, this was monitored by the Fmoc and
TNBS tests. After the coupling of Cbz-l-alanine with the resin, the title compound was cleaved o.
The cleaving mixture (TFA/DCM/TIS, ratio 5:95:1 eq) was removed by evaporation under reduced
pressure and washed with petroleum ether (40–60 C) to obtain the product as white crystals (0.23 g,
58%). The reaction and the work up were monitored by TLC (eluent: ethyl acetate and 1 drop of glacial
acetic acid, Rf: 0.07). Mp: 186–187 C; 1H-NMR (300 MHz, DMSO-d6) H 16.18 (1H, br s, 9-H), 8.54 (1H,
d, J = 7.5 Hz, 4-H), 7.35 (6H, m, 8,13-15-H), 5.23 (1H, quint, J = 7.2 Hz, 2-H), 5.05 (1H, d, J = 12.6 Hz,
11-Ha), 5.00 (1H, d, J = 12.6 Hz, 11-Hb), 4.09 (1H, quint, J = 7.2 Hz, 6-H), 1.50 (3H, d, J = 7.2 Hz, 3-H),
1.20 (3H, d, J = 7.2 Hz, 7-H); 13C-NMR (75.5 MHz, DMSO-d6) C 172.1 (5-C), 158.3 (1-C), 155.6 (10-C),
137.0 (12-C), 128.3 (14-C), 127.7 (15-C), 127.7 (13-C), 65.3 (11-C), 49.8 (6-C), 40.3 (2-C), 19.2 (7-C), 17.9
(3-C); max/cm–1 3287 (N-H), 3264 (N-H), 1684 (C=O), 1655 (C=O), 1535 (N-H), 1230 (C-O); MS(ESI)
m/z 319.2 (M + H)+; CHN [Found: C, 53.06; H, 5.64; N, 26.58. C14H18N6O3 requires C, 52.82; H, 5.70; N,
26.40%].
(2S)-2-amino-N-[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]propanamide (14a-LL) [19]: Cbz-l-alanyl-1-l-
aminoethyltetrazole (13a-LL, 0.58 g, 1.83 mmol) was deprotected by general method E. Following
filtration, the solid residue was washed with methanol, which was discarded. The solid residue was
washed into a separate flask with water, then freeze dried to give the product as a white solid (0.29 g,
86%). Further purification was performed by Prep HPLC method A. The reaction and the work up
were monitored by TLC (eluent: ethanol, Rf: 0.07). Mp: 200 C (decomposed); 1H-NMR (300 MHz,
D2O) H 5.25 (1H, quart, J = 6.9 Hz, 2-H), 3.57 (1H, quart, J = 6.9 Hz, 6-H), 1.52 (3H, d, J = 7.2 Hz, 3-H),
1.25 (3H, d, J = 7.2 Hz, 7-H); 13C-NMR (75.5 MHz, D2O) C 176.2 (5-C), 164.3 (1-C), 49.9 (6-C), 42.0
(2-C), 19.4 (3-C), 19.2 (7-C); max/cm–1 3247 (N-H), 1643 (C=O) 1561 (N-H); MS(ESI) m/z 185.1 (M +
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H)+; HRMS (Found (M+H)+ 185.1145. Calcd. for C6H13ON6: (M + H)+ 185.1145.); (Purity test: HPLC
method A).
Benzyl-N-[(1S)-1-{[(1R)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}ethyl]carbamate (13a-LD) [18]: Prepared
using general method G. The Fmoc group of Fmoc-1-d-aminoethyltetrazole attached to 2-chlorotrityl
chloride resin (resin:loading; 1:1 ratio; 1.2 mmol) was removed, this was monitored by the Fmoc and
TNBS tests. After the coupling of Cbz-l-alanine with the resin, the title compound was cleaved o.
The cleaving mixture (TFA/DCM/TIS, ratio 5:95:1 eq) was removed by evaporation under reduced
pressure, and the residue washed with petroleum ether (40–60 C) to obtain the product as white
crystals (0.34 g, 89%). The reaction and the work up were monitored by TLC (eluent: ethyl acetate and
1 drop of glacial acetic acid, Rf: 0.07). Mp: 166–168 C; 1H-NMR (300 MHz, DMSO-d6) H 8.56 (1H,
d, J = 7.5 Hz, 4-H), 7.35 (6H, m, 8,13-15-H), 5.23 (1H, quint, J = 7.2 Hz, 2-H), 5.04 (1H, d, J = 12.9 Hz,
11-Ha), 5.00 (1H, d, J = 12.6 Hz, 11-Hb), 4.10 (1H, quint, J = 7.5 Hz, 6-H), 1.50 (3H, d, J = 7.2 Hz, 3-H),
1.23 (3H, d, J = 6.9 Hz, 7-H); 13C-NMR (75.5 MHz, DMSO-d6) C 172.6 (5-C), 158.0 (1-C), 156.1 (10-C),
137.4 (12-C), 128.8 (14-C), 128.2 (15-C), 128.2 (13-C), 65.9 (11-C), 50.4 (6-C), 40.3 (2-C), 19.6 (3-C), 18.8
(7-C); max/cm–1 3289 (N-H), 2988, 2874, 2756, 2612 (tetrazole), 1682 (C=O), 1651 (C=O), 1528 (N-H),
1224 (C-O); MS(ESI) m/z 319.1 (M + H)+; CHN [Found: C, 53.10; H, 5.78; N, 26.01. C14H18N6O3 requires
C, 52.82; H, 5.70; N, 26.40%].
(2S)-2-Amino-N-[(1R)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]propanamide (14a-LD) [18]: Cbz-l-alanyl-1-d-
aminoethyltetrazole (13a-LD, 0.58 g, 1.83 mmol) was deprotected by general method E. Following
filtration, the solid residue was washed with ethanol, which was discarded. The solid residue was
washed into a separate flask with water, which was freeze dried and purified by column chromatography
(eluent: ethyl acetate – ethanol 4:1, 2:1, 1:1 then 0:1 ratio) to give the pure product as white solid (98 mg,
58%). The reaction and the work up were monitored by TLC (eluent: ethanol, Rf: 0.13). Mp: 69 C
(phase change), 177 C (melted); 1H-NMR (300 MHz, D2O) H 5.24 (1H, quart, J = 6.6 Hz, 2-H), 4.00
(1H, quart, J = 6.6 Hz, 6-H), 1.52 (3H, d, J = 7.5 Hz, 3-H), 1.48 (3H, d, J = 7.8 Hz, 7-H); 13C-NMR
(75.5 MHz, D2O) C 170.5 (5-C), 164.0 (1-C), 49.3 (6-C), 42.3 (2-C), 19.1 (3-C), 16.7 (7-C); max/cm–1 3204
(N-H), 1667 (C=O), 1539 (N-H); MS(ESI) m/z 185.1 (M + H)+; HRMS (Found (M + H)+ 185.1145. Calcd.
for C6H13ON6: (M + H)+ 185.1145.); (Purity test: HPLC method A).
(S)-Benzyl-(3-((1-(1H-tetrazol-5-yl)ethyl)amino)-3-oxopropyl)carbamate (13d-L): Prepared using general
method G. The Fmoc group of Fmoc-1-l-aminoethyltetrazole attached to the 2-chlorotrityl chloride
resin (resin:loading; 1:1 ratio; 1.3 mmol) was removed, this was monitored by the Fmoc and TNBS
tests. After the coupling of Cbz--alanine with the resin, the title compound was cleaved o. The
cleaving mixture (TFA/DCM/TIS, ratio 5:95:1 eq) was removed by evaporation under reduced pressure,
and the residue washed with petroleum ether (40–60 C) to obtained the product as white crystals
(0.28 g, 67%). The reaction and the work up were monitored by TLC (eluent: ethyl acetate and 1 drop
of glacial acetic acid, Rf: 0.39). Mp: 147–148 C; 1H-NMR (300 MHz, DMSO-d6) H 16.08 (1H, brs, 9-H),
8.56 (1H, d, J = 7.5 Hz, 4-H), 7.35 (5H, m, 13-15-H), 7.21 (1H, m, 8-H), 5.22 (1H, quint, J = 7.2 Hz, 2-H),
5.02 (2H, s, 11-H), 3.24 (2H, quart, J = 6.9Hz, 7-H), 2.34 (2H, t, J = 6.9 Hz, 6-H), 1.48 (3H, d, J = 7.2 Hz,
3-H); 13C-NMR (75,5 MHz, DMSO-d6) C 170.6 (5-C), 158.8 (1-C), 156.5 (10-C), 137.6 (12-C), 128.8 (2C,
14-C), 128.2 (15-C), 128.1 (2C, 13-C), 65.7 (11-C), 40.9 (2-C), 37.3 (7-C), 35.9 (6-C), 19.6 (3-C); max/cm–1
3323 (N-H), 3273 (N-H), 2994, 2882, 2746, 2615 (tetrazole), 1692 (C=O), 1645 (C=O); MS(ESI) (M + Na)+
found 341.2 m/z; HRMS (Found (M + H)+ 319.1516. Calcd. for C14H19O3N6: (M + H)+ 319.1513.);
(Purity test: HPLC method C).
3-Amino-N-[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]propanamide (14d-L): Cbz--alanyl-1-l-amino-
ethyltetrazole (13d-L, 0.20 g, 0.63 mmol) was deprotected by general method E. Following filtration,
the solid residue was washed with methanol, which was discarded. The solid residue was washed into
a separate flask with water, which was freeze dried to give the product as a light brown hygroscopic
amorphous solid (0.09 g, 78%). Further purification was performed by Prep HPLC method A. 1H-NMR
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(300 MHz, D2O) H 5.21 (1H, quart, J = 6.9 Hz, 2-H), 3.17 (2H, m, 7-H), 2.63 (2H, t, J = 6.6 Hz, 6-H), 1.48
(3H, d, J = 6.9 Hz, 3-H); 13C-NMR (75,5 MHz, DMSO-d6) C 171.6 (5-C), 164.5 (1-C), 40.0 (2-C), 35.8
(7-C), 32.5 (6-C), 19.3 (3-C); max/cm–1 3232 (N-H), 1641 (C=O); MS(ESI) (M+H)+ found 185.1 m/z;
HRMS (Found (M + H)+ 185.1145. Calcd. for C6H13ON6: (M + H)+ 185.1145.); (Purity test: HPLC
method A).
Benzyl-N-[(1S)-1-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}butyl]carbamate (13e-LL): Prepared
using general method G. The Fmoc group of Fmoc-1-l-aminoethyltetrazole attached to 2-chlorotrityl
chloride resin (resin:loading; 1:1 ratio; 1.2 mmol) was removed, this was monitored by the Fmoc and
TNBS tests. After the coupling of Cbz-L-norvaline with the resin, the title compound was cleaved o.
The cleaving mixture (TFA/DCM/TIS, ratio 5:95:1 eq) was removed by evaporation under reduced
pressure, and the residue washed with petroleum ether (40–60 C) to obtain the product as white
crystals (0.21, 51%). The reaction and the work up were monitored by TLC (eluent: ethyl acetate and 1
drop of glacial acetic acid, Rf: 0.2). Mp: 175–178 C; 1H-NMR (300 MHz, DMSO-d6) H 16.22 (1H, brs,
11-H), 8.55 (1H, d, J = 7.5, 4-H), 7.35 (6H, m, 10, 15-17-H), 5.23 (1H, quint, J = 7.2 Hz, 2-H), 5.02 (2H, s,
13-H), 4.04 (1H, m, 6-H), 1.59 (2H, m, 7-H), 1.49 (3H, d, J = 6.9 Hz, 3-H), 1.27 (2H, m, 8-H), 0.84 (3H, t,
J = 7.2 Hz, 9-H); 13C-NMR (75.5 MHz, DMSO-d6) C 172.2 (5-C), 159.1 (1-C), 156.4 (12-C), 137.5 (14-C),
128.8 (2C, 16-C), 128.2 (17-C), 128.1 (2C, 15-C), 65.8 (13-C), 54.6 (6-C), 40.9 (2-C), 34.3 (7-C), 19.7 (3-C),
19.1 (8-C), 14.0 (9-C); max/cm–1 3310 (N-H), 3271 (N-H), 2959, 2877, 2752, 2609 (tetrazole), 1682 (C=O),
1651 (C=O), 1533 (N-H), 1234 (C-O); MS(ESI) m/z 369.2 (M + Na)+; HRMS (Found (M + H)+ 347.1830.
Calcd. for C16H23O3N6: (M + H)+ 347.1826.); (Purity test: HPLC method D)
(S)-N-((S)-1-(1H-tetrazol-5-yl)ethyl)-2-aminopentanamide (14e-LL): Cbz-l-norvalyl-1-l-amino-ethyltetrazole
(13e-LL, 0.10 g, 0.29 mmol) was deprotected by general method E. Following filtration, the solid residue
was washed with methanol, which was discarded. The residue was washed with water, then freeze dried
to give the product as a white solid (47 mg, 77%). Further purification was performed by Prep HPLC
method A. The reaction and the work up were monitored by TLC (eluent: ethanol, Rf: 0.16). Mp: 251–254
C; 1H-NMR (300 MHz, D2O) H 5.28 (1H, quart, J = 7.2 Hz, 2-H), 3.79 (1H, t, J = 6.6 Hz, 6-H), 1.70 (2H, m,
7-H), 1.54 (3H, d, J = 6.9 Hz, 3-H), 1.21 (2H, m, 8-H), 0.81 (3H, t, J = 7.2 Hz, 9-H); 13C-NMR (75.5 MHz,
DMSO-d6) C 171.2 (5-C), 164.7 (1-C), 53.5 (6-C), 42.0 (2-C), 33.8 (7-C), 19.1 (3-C), 17.6 (8-C), 12.8 (9-C);
max/cm–1 3210 (N-H), 1687 (C=O), 1551 (N-H); MS(ESI) m/z 213.1 (M + H)+; HRMS (Found (M + H)+
213.1458. Calcd. for C8H17ON6: (M + H)+ 213.1460.); (Purity test: HPLC method A).
Benzyl-N-[(1S)-3-methyl-1-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}butyl]carbamate (13h-LL):
Prepared using general method G. The Fmoc group of Fmoc-1-l-aminoethyltetrazole attached to
2-chlorotrityl chloride resin (resin:loading; 1:2 ratio; 1.5 mmol) was removed, this was monitored by
the Fmoc and TNBS tests. After the coupling of Cbz-l-leucine with the resin, the title compound was
cleaved o. The cleaving mixture (TFA/DCM/TIS, ratio 5:95:1 eq) was removed by evaporation under
reduced pressure, and the residue washed with petroleum ether (40–60 C) to obtain the product as
white crystals (0.45, 84%). The reaction and the work up were monitored by TLC (eluent: ethyl acetate –
ethanol – drop of glacial acetic acid 1:1 ratio, Rf: 0.64). Mp: 149–150 C; 1H-NMR (300 MHz, DMSO-d6)
H 16.1 (1H, brs, 11-H), 8.55 (1H, d, J = 7.5 Hz, 4-H), 7.36 (6H, m, 10,15,16,17-H), 5.22 (1H, quint, J
= 6.9 Hz, 2-H), 5.04 (1H, d, J = 12.6, 13a-H), 5.00 (1H, d, J = 12.6 Hz, 13a-H), 4.07 (1H, m, 6-H), 1.60
(1H, m, 8-H), 1.49 (3H, d, J = 7.2 Hz, 3-H), 1.42 (2H, m, 7-H), 0.85 (3H, d, J = 6.6 Hz, 9a-H), 0.84 (3H,
d, J = 6.6 Hz, 9b-H); 13C-NMR (75.5 MHz, DMSO-d6) C 172.6 (5-C), 156.4 (12-C), 137.5 (14-C), 128.8
(16-C), 128.2 (17-C), 128.1 (15-C), 65.8 (13-C), 53.3 (6-C), 41.0 (2-C), 40.3 (7-C), 24.6 (8-C), 23.6 (9a-C), 21.8
(9b-C), 19.6 (3-C); max/cm–1 3316 (N-H), 3271 (N-H), 2961, 2876, 2743, 2615 (tetrazole), 1682 (C=O),
1653 (C=O), 1530 (N-H), 1233 (C-O); MS(ESI) m/z 360.8 (M + H)+; CHN [Found: C, 56.82.; H, 6.68; N,
23.05. C17H24N6O3 requires C, 56.65; H, 6.71; N, 23.32%].
(2S)-2-Amino-4-methyl-N-[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]pentanamide (14h-LL): Cbz-l-leucyl-1-l-
aminoethyltetrazole (13h-LL, 0.95 g, 2.6 mmol) was deprotected by general method E. Following
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filtration, the solid residue was washed with ethanol, which was discarded. The residue was washed
with water, then freeze dried and washed with diethyl ether to give the product as a white solid (0.48 g,
81%). Further purification was performed by Prep HPLC method A. The reaction and the work up
were monitored by TLC (eluent: ethanol, Rf: 0.3). Mp: 210 C (decomposed); 1H-NMR (300 MHz, D2O)
H 5.28 (1H, quart, J = 7.2 Hz, 2-H), 3.49 (1H, t, J = 7.2Hz, 6-H), 1.53 (3H, d, J = 7.2 Hz, 3-H), 1.44 (3H,
m, 7,8-H), 0.82 (3H, d, J = 4.8 Hz, 9a-H), 0.80 (3H, d, J = 5.1 Hz, 9b-H); 13C-NMR (75.5 MHz, DMSO-d6)
C 175.6 (5-C), 169.7 (1-C), 52.9 (6-C), 42.7 (7-C), 41.8 (2-C), 24.0 (8-C), 21.9 (9a-C), 21.4 (9b-C), 16.8 (3-C);
max/cm–1 3219 (N-H), 1653 (C=O), 1562 (N-H); MS(ESI) m/z 227.2 (M + H)+; HRMS (Found (M + Na)+
249.1436. Calcd. for C9H18ON6Na: (M + Na)+ 249.1434.); (Purity test: HPLC method A).
Benzyl-N-[(1S)-3-methyl-1-{[(1R)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}butyl]carbamate (13h-LD):
Prepared using general method G. The Fmoc group of Fmoc-1-d-aminoethyltetrazole attached to
2-chlorotrityl chloride resin (resin:loading; 1:1 ratio; 1.2 mmol) was removed, this was monitored by
Fmoc and TNBS tests. After the coupling of Cbz-l-leucine with the resin, the title compound was
cleaved o. The cleaving mixture (TFA/DCM/TIS, ratio 5:95:1 eq) was removed by evaporation under
reduced pressure, and washed with petroleum ether (40–60 C) to obtain the product as white crystals
(0.30 g, 69%). The reaction and the work up were monitored by TLC (eluent: ethyl acetate – ethanol
1:1 ratio, Rf: 0.63). Mp: 143–144 C; 1H-NMR (300 MHz, DMSO-d6) H 16.2 (1H, brs, 11-H), 8.61 (1H,
d, J = 7.5 Hz, 4-H), 7.35 (6H, m, 10,15,16,17-H), 5.26 (1H, quint, J = 7.5 Hz, 2-H), 5.04 (1H, d, J = 13.2,
13a-H), 5.00 (1H, d, J = 12.9 Hz, 13a-H), 4.11 (1H, m, 6-H), 1.61 (1H, m, 8-H), 1.45 (3H, d, J = 6.9 Hz, 3-H),
1.42 (2H, m, 7-H), 0.88 (3H, d, J = 6.0 Hz, 9a-H), 0.86 (3H, d, J = 5.7 Hz, 9b-H); 13C-NMR (75.5 MHz,
DMSO-d6) C 172.4 (5-C), 158.5 (1-C), 156.4 (12-C), 137.5 (14-C), 128.8 (16-C), 128.2 (17-C), 128.1 (15-C),
65.9 (13-C), 53.4 (6-C), 41.4 (2-C), 40.3 (7-C), 24.7 (8-C), 23.5 (9a-C), 21.9 (9b-C), 19.6 (3-C); max/cm–1
3312 (N-H), 3269 (N-H), 2959, 2876, 2756, 2621 (tetrazole) 1690 (C=O), 1649 (C=), 1528 (N-H), 1234
(C-O); MS(ESI) m/z 361.2 (M + H); HRMS (Found (M + H)+ 361.1987. Calcd. for C17H25O3N6: (M +
H)+ 361.1983.); (Purity test: HPLC method D).
(2S)-2-Amino-4-methyl-N-[(1R)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]pentanamide (14h-LD): Cbz-l-leucyl-1-d-
aminoethyltetrazole (13h-LD, 0.25 g, 0.7 mmol) was deprotected by general method E. Following
filtration, the solid residue was washed with ethanol, which was discarded. The residue was washed
with water, which was freeze dried and purified by column chromatography (eluent: ethyl acetate –
ethanol 1:1 – 1:2 – 0:1) to give the pure product as a white solid (83 mg, 53%). The reaction and the work
up were monitored by TLC (eluent: ethanol, Rf: 0.21). Mp: 136 C (decomposed), 161 C (melted);
1H-NMR (300 MHz, D2O) H 5.27 (1H, quart, J = 6.9 Hz, 2-H), 3.95 (1H, t, J = 6.9Hz, 6-H), 1.71 (3H,
m, 7,8-H), 1.53 (3H, d, J = 7.2 Hz, 3-H), 0.93 (3H, d, J = 6.0 Hz, 9a-H), 0.91 (3H, d, J = 6.0 Hz, 9b-H);
13C-NMR (75.5 MHz, DMSO-d6) C 169.8 (5-C), 164.7 (1-C), 52.2 (6-C), 42.4 (2-C), 39.9 (7-C), 24.0 (8-C),
21.6 (9a-C), 21.3 (9b-C), 19.1 (3-C); max/cm–1 3194 (N-H), 1667 (C=O), 1543 (N-H); MS(ESI) m/z 227.2
(M + H)+; HRMS (Found (M + H)+ 227.1625 Calcd. for C9H19ON6: (M + H)+ 227.1620.); (Purity test:
HPLC method A).
Benzyl-N-[(1S,2S)-2-methyl-1-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}butyl]carbamate (13i-LL):
Prepared using general method G. The Fmoc group of Fmoc-1-l-aminoethyltetrazole attached to
2-chlorotrityl chloride resin (resin:loading; 1:1 ratio; 1.8 mmol) was removed, this was monitored by
the Fmoc and TNBS tests. After the coupling of Cbz-L-isoleucine with the resin, the title compound
was cleaved o. The cleaving mixture (TFA/DCM/TIS, ratio 5:95:1 eq) was removed by evaporation
under reduced pressure, and washed with petroleum ether (40–60 C) to obtain the product as white
crystals (0.40 g, 62%). The reaction and the work up were monitored by TLC (eluent: ethyl acetate –
ethanol 10:1 ratio, Rf: 0.13). Mp: 186–189 C; 1H-NMR (300 MHz, DMSO-d6) H 8.58 (1H, d, J = 7.2 Hz,
4-H), 7.35 (5H, m, 16,17,18-H), 7.24 (1H, d, J = 9.0 Hz, 11-H), 5.24 (1H, quint, J = 6.9 Hz, 2-H), 5.05 (1H,
d, J = 12.6 Hz, 14a-H), 5.00 (1H, d, J = 12.6 Hz, 14b-H), 3.92 (1H, t, J = 8.1 Hz, 6-H), 1.70 (1H, m, 7-H),
1.50 (3H, d, J = 6.9 Hz, 3-H), 1.35 (1H, m, 9a-H), 1.07 (1H, m, 9b-H), 0.77 (3H, t, J = 7.5 Hz, 10-H), 0.75
(3H, d, J = 7.5 Hz, 8-H); 13C-NMR (75.5 MHz, DMSO-d6) C 171.4 (5-C), 158.3 (1-C), 156.5 (13-C), 137.5
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(15-C), 128.8 (17-C), 128.2 (18-C), 128.1 (16-C), 65.9 (14-C), 59.3 (6-C), 39.9 (2-C), 36.9 (7-C), 24.7 (9-C),
19.5 (3-C), 15.7 (8-C), 11.3 (10-C); max/cm–1 3279 (N-H), 2963, 2878, 2693, 2608 (tetrazole), 1690 (C=O),
1651 (C=O), 1535 (N-H), 1234 (C-O); MS(ESI) m/z 361.1 (M + H)+; CHN [Found: C, 56.61.; H, 6.77; N,
23.01. C17H24N6O3 requires C, 56.65; H, 6.71; N, 23.32%].
(2S,3S)-2-amino-3-methyl-N-[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]pentanamide (14i-LL): Cbz-l-isoleucyl-
1-l-aminoethyltetrazole (13i-LL, 0.35 g, 0.9 mmol) was deprotected by general method E. Following
filtration, the solid residue was washed with ethanol, which was discarded. The residue was washed
with water, which was freeze dried to give the product as white solid (190 mg, 86%). Due to
hygroscopicity, the corresponding hydrochloride salt was made with 2M HCl in diethyl ether solution
(20 mL) for characterization. Further purification was performed by Prep HPLC method A. The reaction
and the work up were monitored by TLC (eluent: ethanol, Rf: 0.31). Mp: 164 - 167 C (melted and
decomposed); 1H-NMR (300 MHz, D2O) H 5.39 (1H, quart, J = 7.2 Hz, 2-H), 3.85 (1H, d, J = 5.7 Hz,
6-H), 1.92 (1H, m, 7-H), 1.65 (3H, d, J = 7.2 Hz, 3-H), 1.31 (1H, m, 9a-H), 1.14 (1H, m, 9b-H), 0.89 (3H, d,
J = 6.9 Hz, 8-H), 0.83 (3H, t, J = 7.5 Hz, 10-H); 13C-NMR (75.5 MHz, DMSO-d6) C 169.1 (5-C), 158.1
(1-C), 57.7 (6-C), 40.7 (2-C), 36.3 (7-C), 23.9 (9-C), 17.6 (3-C), 14.1 (8-C), 10.4 (10-C); max/cm–1 3240
(N-H), 1682 (C=O), 1574 (N-H); MS(ESI) m/z 227.2 (M + H)+; HRMS (Found (M + Na)+ 249.1436. Calcd.
for C9H18ON6Na: (M + Na)+ 249.1434.); (Purity test: HPLC method A).
Benzyl-(5S)-2-oxo-5-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}pyrrolidine-1-carboxylate (13f-LL):
Prepared using general method G. The Fmoc group of the Fmoc-1-l-aminoethyltetrazole attached
to 2-chlorotrityl chloride resin (resin:loading; 1:2 ratio; 2.0 mmol) was removed. After coupling
of Cbz-L-pyroglutamine with the resin, the title compound was cleaved o. The cleaving mixture
(TFA/DCM/TIS, ratio 5:95:1 eq) was subsequently removed by evaporation under reduced pressure.
The crude product was purified by column chromatography (eluent: ethyl acetate – ethanol 10:1, 6:1
then 1:1 ratio) to obtain the product as white crystals (0.46g, 65%). The reaction and the work up were
monitored by TLC (eluent: ethyl acetate – ethanol 10:1, Rf: 0.09). Mp: 195 C (decomposed); 1H-NMR
(300 MHz, DMSO-d6) H 16.05 (1H, brs, 11-H), 8.93 (1H, d, J = 7.5 Hz, 4-H), 7.36 (5H, m, 15-17-H), 5.17
(3H, m, 2,13-H), 4.64 (1H, dd, J = 2.7 Hz, J = 9.0 Hz, 6-H), 2.41 (2H, m, 8-H), 2.26 (1H, m, 7-Ha), 1.94
(1H, m, 7-Hb), 1.42 (3H, d, J = 6.9 Hz, 3-H); 13C-NMR (75.5 MHz, DMSO-d6) C 174.1 (9-C), 171.0 (5-C),
158.3 (1-C), 150.9 (12-C), 136.0 (14-C), 128.8 (2C, 16-C), 128.5 (17-C), 128.0 (15-C), 67.5 (13-C), 59.3 (6-C),
40.2 (2-C), 31.3 (8-C), 22.3 (7-C), 19.6 (3-C); max/cm–1 3289 (N-H), 2993, 2868, 2739, 2615 (tetrazole),
1780 (C=O), 1701 (C=O), 1655 (C=O), 1545 (N-H), 1236 (C-O); MS(ESI) m/z 381.2 (M + Na)+. CHN
[Found: C, 53.63; H, 5.10; N, 23.18. C16H18N6O4 requires C, 53.63; H, 5.06; N, 23.45%].
(S)-N-((S)-1-(1H-tetrazol-5-yl)ethyl)-5-oxopyrrolidine-2-carboxamide (14f-LL): Cbz-l-pyroglutamyl-1-l-
aminoethyltetrazole (13f-LL, 0.44 g, 1.2 mmol) was reacted by general method E. Following filtration,
the solid residue was washed with methanol and the filtrate was evaporated under reduced pressure.
The residual oil was triturated with diethyl ether to give the title compound as a white solid (0.23 g,
84%). Further purification was performed by Prep HPLC method A. The reaction and the work up
were monitored by TLC (ethanol, Rf: 0.3). Mp: 160 C (decomposed); 1H-NMR (300 MHz, D2O) H
5.35 (1H, quart, J = 7.2 Hz, 2-H), 4.34 (1H, dd, J = 4.8 Hz, J = 8.4 Hz, 6-H), 2.52 (1H, m, 7-Ha), 2.40 (2H,
m, 8-H) 2.04 (1H, m, 7-Hb), 1.61 (3H, d, J = 6.9 Hz, 3-H); 13C-NMR (75.5 MHz, D2O) C 182.3 (9-C),
174.6 (5-C), 159.0 (1-C), 56.9 (6-C), 41.0 (2-C), 29.3 (8-C), 25.0 (7-C), 18.1 (3-C); max/cm–1 3262 (N-H),
1649 (C=O), 1547 (N-H); MS(ESI) m/z 225.1 (M + H)+. HRMS (Found (M + H)+ 225.1096. Calcd. for
C8H13O2N6: (M + H)+ 225.1095.); (Purity test: HPLC method A).
Benzyl-N-[(1S)-2-phenyl-1-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}ethyl]carbamate (13j-LL):
Prepared using general method G. The Fmoc group of Fmoc-1-l-aminoethyltetrazole attached to
2-chlorotrityl chloride resin (resin:loading; 1:1 ratio; 1.0 mmol) was removed, this was monitored
by the Fmoc and TNBS tests. After the coupling of Cbz-l-phenylalanine with the resin, the title
compound was cleaved o. The cleaving mixture (TFA/DCM/TIS, ratio 5:95:1 eq) was removed by
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evaporation under reduced pressure, and washed with petroleum ether (40–60 C) to obtain the
product as white crystals (0.32 g, 79%). Further purification was performed using a CombiFlash
EZ Prep system (Teledyne-ISCO, Lincoln, NE, USA, eluent: gradient: dichloromethane – methanol
0–30%). The reaction and the work up were monitored by TLC (eluent: ethyl acetate, Rf: 0.11). Mp:
191–193 C; 1H-NMR (300 MHz, DMSO-d6) H 16.21 (1H, brs, 8.72 (1H, d, J = 7.5 Hz, 4-H), 7.44 (1H, d,
J = 8.7 Hz, 12-H), 7.33 - 7.24 (10H, m, 9,10,11,17,18,19-H), 5.27 (1H, quint, 6.9 Hz, 2-H), 4.96 (1H, d,
J = 13.5 Hz, 15a-H), 4.92 (1H, d, J = 13.5 Hz, 15b-H), 4.30 (1H, m, 6-H), 3.03 (1H, dd, J = 3.3 Hz, J =
13.8 Hz, 7a-H), 2.72 (1H, dd, J = 10.8 Hz, J = 13.5 Hz, 7b-H), 1.52 (3H, d, J = 6.9 Hz, 3-H); 13C-NMR
(75.5 MHz, DMSO-d6) C 171.7 (5-C), 158.7 (1-C), 156.3 (14-C), 138.5 (8-C), 137.5 (16-C), 129.6, 128.7,
128.5, 128.1, 127.9, 126.7 (9,10,11,17,18,19-C), 65.7 (15-C), 56.5 (6-C), 40.0 (2-C), 37.8 (7-C), 19.7 (3-C);
max/cm–1 3300 (N-H), 2984, 2874, 2741, 2615 (tetrazole), 1684 (C=O), 1651 (C=O), 1531 (N-H), 1234
(C-O); MS(ESI) m/z 417.2 (M + Na)+; CHN [Found: C, 60.78; H, 5.68; N, 20.92. C20H22N6O3 requires C,
60.90; H, 5.62; N, 21.31%].
(2S)-2-Amino-3-phenyl-N-[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]propanamide (14j-LL): Cbz-l-phenylalanyl-
1-l-aminoethyltetrazole (13j-LL, 0.30 g, 0.8 mmol) was deprotected by general method E. Following
filtration, the solid residue was washed with ethanol, which was discarded. The residue was washed
with water, which was freeze dried, then purified by column chromatography (eluent: dichloromethane
– ethanol 10:1, 8:1, 6:1, 1:1 then 0:1 ratio) to give the pure product as a white solid (40 mg, 20%). Further
purification was performed by Prep HPLC method A. The reaction and the work up were monitored
by TLC (eluent: ethanol, Rf: 0.39). Mp: 152–155 C; 1H-NMR (300 MHz, D2O) H 7.15 (3H, m, 10,11-H),
7.01 (2H, m, 9-H), 5.24 (1H, quart, J = 6.9 Hz, 2-H), 3.77 (1H, m, 6-H), 2.97 (1H, dd, J = 6.0, J = 13.5 Hz,
7a-H), 2.89 (1H, dd, J = 7.8, J = 13.5 Hz, 7b-H), 1.43 (3H, d, J = 7.2 Hz, 3-H); 13C-NMR (75.5 MHz, D2O)
C 163.5 (1-C), 150.6 (5-C), 135.5 (8-C), 129.2 (9-C), 128.6 (10-C), 127.1 (11-C), 55.5 (6-C), 41.3 (2-C), 39.3
(7-C), 19.3 (3-C); max/cm–1 3217 (N-H), 1651 (C=O), 1528 (N-H); MS(ESI) m/z 283.2 (M + Na)+. HRMS
(Found (M + H)+ 261.1462. Calcd. for C12H17ON6: (M + H)+ 261.1458.); (Purity test: HPLC method A).
Benzyl-N-[(1S)-1-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)propyl]carbamoyl}ethyl]carbamate (13b-LL): Prepared
using general method G. The Fmoc group of the Fmoc-1-l-aminopropyltetrazole attached to
2-chlorotrityl chloride resin (resin:loading; 1:1 ratio; 2.9 mmol) was removed. After coupling of
Cbz-l-alanine with the resin, the title compound was cleaved o. The cleaving mixture (TFA/DCM/TIS,
ratio 5:95:1 eq) was removed by evaporation under reduced pressure. The crude product was
subsequently washed with petroleum ether (40–60 C) to obtain the product as white crystals (0.49 g,
52%). Mp: 174–175 C; 1H-NMR (300 MHz, DMSO-d6) H 8.44 (1H, d, J = 7.5 Hz, 5-H), 7.41 (1H, d, J =
7.2 Hz, 9-H), 7.34 (5H, m, 14,15,16-H), 5.06 (1H, m, 2-H), 5.02 (2H, s, 12-H), 4.10 (1H, quint, J = 6.9 Hz,
7-H), 1.88 (2H, m, 3-H), 1.19 (3H, d, J = 7.2 Hz, 8-H), 0.87 (3H, t, J = 7.2 Hz, 4-H); 13C-NMR (75.5 MHz,
DMSO-d6) C 173.0 (6-C), 156.8 (1-C), 156.1 (11-C), 137.5 (13-C), 128.8 (15-C), 128.2 (16-C), 128.1 (14-C),
65.8 (12-C), 50.4 (7-C), 45.8 (2-C), 26.8 (3-C), 18.4 (8-C), 10.6 (4-C); max/cm–1 3300 (N-H), 3265 (N-H),
2976, 2876, 2735, 2617 (tetrazole), 1691 (C=O), 1651 (C=O), 1533 (N-H), 1246 (C-O); MS(ESI) m/z 333.1
(M + H)+; CHN [Found: C, 54.20; H, 6.11; N, 24.91. C15H20N6O3 requires C, 54.21; H, 6.07; N, 25.29%].
(2S)-2-Amino-N-[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)propyl]propanamide (14b-LL): Cbz-l-alanyl-1-l-
aminopropyltetrazole (13b-LL, 0.40 g, 1.2 mmol) was deprotected by general method E. Following
filtration, the solid residue was washed with ethanol, which was discarded. The residue was washed
with water, which was freeze dried to give the product as a white solid (206 mg, 86%). Due to poor
solubility, the corresponding hydrochloride salt was prepared using 2M HCl in diethyl ether solution
(20 mL) for characterization (hygroscopic solid). Further purification was performed by Prep HPLC
method A. The reaction and the work up were monitored by TLC (eluent: ethanol, Rf: 0.12). 1H-NMR
(300 MHz, DMSO-d6) H 9.17 (1H, d, J = 7.6 Hz, 5-H), 8.34 (3H, brs, 9-H), 5.09 (1H, quart, J = 7.8 Hz,
2-H), 3.93 (1H, quart, J = 6.7 Hz, 7-H), 1.92 (2H, m, 3-H), 1.38 (3H, d, J = 7.0 Hz, 8-H), 0.90 (3H, t, J = 7.4
Hz, 4-H); 13C-NMR (75.5 MHz, DMSO-d6) C 170.0 (6-C), 158.0 (1-C), 48.6 (7-C), 46.4 (2-C), 26.8 (3-C),
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17.4 (8-C), 10.6 (4-C); IR; MS(ESI) m/z 199.1 (M + H)+; HRMS (Found (M + H)+ 199.1302. Calcd. for
C7H15ON6: (M + H)+ 199.1302.); (Purity test: HPLC method A).
N-[(1S)-1-{[(1S)-1-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}ethyl]carbamoyl} ethyl]carbamate (13
-LLL): Prepared using general method G. The Fmoc group of Fmoc-1-l-aminoethyltetrazole attached
to the 2-chlorotrityl chloride resin (resin:loading; 1:1 ratio; 1.0 mmol) was removed, this was monitored
by the Fmoc and TNBS tests. After the coupling of Fmoc-l-alanine with the resin, the Fmoc group was
removed again. Finally, Cbz-l-alanine was attached to the resin, and the title compound was cleaved
o. The cleaving mixture (TFA/DCM/TIS, ratio 5:95:1 eq) was removed by evaporation under reduced
pressure, and washed with petroleum ether (40–60 C) to obtain the product as white crystals (0.19 g,
47%). Further purification was performed by Prep HPLC method A. Mp: 199–201 C (melted and
decomposed); 1H-NMR (300 MHz, DMSO-d6) H 16.09 (13-H), 8.48 (1H, d, J = 6.9 Hz, 4-H), 7.93 (1H, d,
J = 7.5 Hz, 8-H), 7.42 (1H, d, J = 7.2 Hz, 12-H), 7.35 (5H, m, 17-19-H), 5.21 (1H, quint, J = 6.9 Hz, 2-H),
5.02 (2H, s, 15-H), 4.29 (1H, quint, J = 7.2 Hz, 6-H), 4.06 (1H, quint, J = 7.2 Hz, 10-H), 1.49 (3H, d, J = 6.9
Hz, 3-H), 1.19 (6H, d, J = 6.9 Hz, 7,11-H); 13C-NMR (75.5 MHz, DMSO-d6) C 172.6 (9-C), 172.3 (5-C),
159.1 (1-C), 156.1 (14-C), 137.5 (16-C), 128.8 (18-C), 128.2 (19-C), 128.1 (17-C), 65.8 (15-C), 50.4 (10-C),
48.4 (6-C), 40.9 (2-C), 19.7 (3-C), 18.5 (7-C), 18.4 (11-C); max/cm–1 3298(N-H), 1694 (C=O), 1643 (C=O),
1526 (N-H), 1219 (C-O); MS(ESI) m/z 390.2 (M + H)+; HRMS (Found (M + H)+ 390.1883. Calcd. for
C17H24O4N7: (M + H)+ 390.1884.); (Purity test: HPLC method C).
(S)-N-((S)-1-(1H-tetrazol-5-yl)ethyl)-2-((S)-2-aminopropanamido)propanamide (14c-LLL): Cbz-l-alanyl-
l-alanyl-1-l-aminoethyltetrazole (13c-LLL, 0.12 g, 0.31 mmol) was reacted by the general method E.
Following the filtration, the solid residue was washed with methanol, then the filtrate was evaporated
under reduced pressure to give the crude product (1.11 g, 95%), further recrystallization from a
methanol - ethyl acetate mixture provided the pure product as white crystals (0.477 g, 40%). Further
purification was performed by Prep HPLC method A. The reaction and the work up were monitored by
TLC (eluent: ethanol, Rf: 0.13). Mp: 135 C (melted and decomposed); 1H-NMR (300 MHz, D2O) H
5.25 (1H, quart, J = 7.2 Hz, 2-H), 4.30 (1H, quart, J = 7.2 Hz, 6-H), 3.95 (1H, quart, J = 6.9 Hz, 10-H), 1.52
(3H, d, J = 7.2 Hz, 3-H), 1.43 (3H, d, J = 7.2 Hz, 11-H), 1.33 (3H, d, J = 7.2 Hz, 7-H); 13C-NMR (75.5 MHz,
D2O) C 173.6 (5-C), 171.7 (9-C), 164.1 (1-C), 49.8 (6-C), 49.0 (10-C), 42.0 (2-C), 19.4 (3-C), 17.0 (11-C),
16.5 (7-C); max/cm–1 3252 (N-H), 1639 (C=O), 1539 (N-H); MS(ESI) m/z 256.1 (M + H)+; HRMS (Found
(M + H)+ 256.1520. Calcd. for C9H18O2N7: (M + H)+ 256.1516.); (Purity test: HPLC method A).
3-{[(1S)-1-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}ethyl]carbamoyl}propanoic acid (16-LL):
Prepared using general method G. The Fmoc group of Fmoc-1-l-aminoethyltetrazole attached to the
2-chlorotrityl chloride resin (resin:loading; 1:2 ratio; 1.4 mmol) was removed. After the coupling of
Fmoc-L-alanine with the resin, the Fmoc group was removed again. Finally, a succinyl group was
attached to the resin using succinic anhydride, and the title compound was cleaved o. The cleaving
mixture (TFA/water/TIS, ratio 95:2.5:2.5) was removed by evaporation under reduced pressure, and
recrystallized from a water – acetone solvent mixture to obtain the product as white crystals (0.16 g,
40%). The reaction and the work up were monitored by TLC (eluent: ethyl acetate – ethanol – drop of
glacial acetic acid 1:1 ratio, Rf: 0.21). Mp: 170–171 C; 1H-NMR (300 MHz, D2O) H 5.32 (1H, quart, J =
7.2 Hz, 2-H), 4.28 (1H, quart, J = 7.2 Hz, 6-H), 2.64 (2H, m, 11-H), 2.54 (2H, m, 10-H), 1.62 (3H, d, J = 6.9
Hz, 3-H), 1.35 (3H, d, J = 7.2 Hz, 7-H); 13C-NMR (75.5 MHz, D2O) C 176.9 (12-C), 175.0 (9-C), 174.9
(5-C), 158.5 (1-C), 49.7 (6-C), 40.7 (2-C), 29.9 (10-C), 29.0 (11-C), 17.8 (3-C), 16.4 (7-C); max/cm–1 3358
(N-H), 3254 (O-H), 2992, 2945, 2886, 2778, 2712 (tetrazole), 1713 (C=O), 1636 (C=O), 1543 (N-H), 1526
(N-H), 1231 (C-O); MS(MALDI) m/z 285.30 (M + H)+; HRMS (Found (M + H)+ 285.1310. Calcd. for
C10H17O4N6: (M + H)+ 285.1306.); (Purity test: HPLC method B).
3-{[(1S)-1-{[(1S)-1-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}ethyl]carbamoyl}ethyl]-carbamoyl}propanoic
acid (17-LLL): Prepared using general method G. The Fmoc group of Fmoc-1-l-aminoethyltetrazole
attached to the 2-chlorotrityl chloride resin (resin:loading; 1:2 ratio; 2.8 mmol) was removed. After the
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coupling of Fmoc-l-alanine with the resin, the Fmoc group was removed, and the free amino group was
coupled with Fmoc-l-alanine again. After removing the Fmoc protection, a succinyl group was attached
to the resin using succinic anhydride, and the title compound was cleaved off. The cleaving mixture
(TFA/water/TIS, ratio 95:2.5:2.5) was removed by evaporation under reduced pressure, and triturated with
diethyl ether to obtain the product as white crystals (0.39 g, 79%). Further purification was performed by
Prep HPLC method A. The reaction and the work up were monitored by TLC (eluent: ethyl acetate –
ethanol – drop of glacial acetic acid 1:1 ratio, Rf: 0.22). Mp: 186 C (melted and decomposed); 1H-NMR
(300 MHz, D2O) H 5.32 (1H, quart, J = 7.2 Hz, 2-H), 4.29 (1H, quart, J = 7.2 Hz, 6-H), 4.21 (1H, quart, J =
7.2 Hz, 10-H), 2.66 (2H, m, 16-H), 2.55 (2H, m, 15-H), 1.62 (3H, d, J = 6.9 Hz, 3-H), 1.35 (3H, d, J = 7.2 Hz,
7-H), 1.34 (3H, d, J = 7.2 Hz, 11-H); 13C-NMR (75.5 MHz, D2O) C 177.0 (17-C), 175.3 (14-C), 175.2 (9-C),
174.6 (5-C), 158.1 (1-C), 50.0 (10-C), 49.6 (6-C), 40.7 (2-C), 29.8 (16-C), 29.0 (15-C), 17.8 (3-C), 16.3 (7-C), 16.2
(11-C); max/cm–1 3343 (N-H), 3381 (O-H), 1707 (C=O), 1651 (C=O), 1634 (C=O), 1539 (N-H), 1201 (C-O);
MS(MALDI) m/z 356.30 (M + H)+. HRMS (Found (M + H)+ 356.1682. Calcd. for C13H22O5N7: (M + H)+
356.1677.) (Purity test: HPLC method A).
3-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamoyl}ethyl]carbamoyl}ethyl]-carbamoyl}
ethyl]carbamoyl}propanoic acid (18-LLLL): Prepared using general method G. The Fmoc group of
Fmoc-1-l-aminoethyltetrazole attached to the 2-chlorotrityl chloride resin (resin:loading; 1:1 ratio;
1.5 mmol) was removed, and resin was coupled with Fmoc-l-alanine, the Fmoc deprotection and
coupling with Fmoc-l-alanine procedure was repeated 2 more times. After removing the Fmoc protection
for the final time, a succinyl group was attached to the resin using succinic anhydride, and the title
compound was cleaved off. The cleaving mixture (TFA/water/TIS, ratio 95:2.5:2.5) was removed by
evaporation under reduced pressure. The residue was triturated with diethyl ether to obtain the product
as a white solid (0.44 g, 68%). Further purification was carried out by column chromatography (eluent:
ethyl acetate – ethanol 4:1, 1:1 then 0:1 ratio) and by Prep HPLC method A. The reaction and the work up
were monitored by TLC (eluent: ethanol, Rf: 0.21). Mp: 231 C (decomposed); 1H-NMR (300 MHz, D2O)
H 5.32 (1H, quart, J = 7.0 Hz, 2-H), 4.26 (3H, m, 6,10,14-H), 2.64 (2H, m, 19-H), 2.58 (2H, m, 18-H), 1.63
(3H, d, J = 7.0 Hz, 3-H), 1.36 (9H, d, J = 7.2 Hz, 7,11,15-H); 13C-NMR (75.5 MHz, D2O) C 177.9 (20-C),
175.5 (17-C), 175.3, 174.9, 174.4 (5,9,13-C), 158.7 (1-C), 50.1, 49.8, 49.6 (6,10,14-C), 40.9 (2-C), 29.9 (18-H),
29.2 (19-H), 18.0 (3-C), 16.4, 16.3, 16.2 (7, 11, 15-C); max/cm–1 3265 (N-H), 1690 (C=O), 1653 (C=O), 1531
(N-H), 1223 (C-O); MS(ESI) m/z 425.1 (M-H)-; HRMS (Found (M + H)+ 427.2047. Calcd. for C16H27O6N8:
(M + H)+ 427.2048.); (Purity test: HPLC method B).
3.3. Microbiology
All MICs were determined using an agar dilution method [41]. This necessitated the use of a
defined antagonist-free medium (peptone-free), prepared as previously described with the inclusion
of 2% saponin-lysed horse blood, 25 g/mL NAD and 25 g/mL haemin [23]. Test compounds were
dissolved in sterile deionised water and incorporated into the antagonist-free medium at a final
concentration range of 1–128 mg/L. All bacteria were prepared from fresh (18 h) subcultures on blood
agar. Each isolate was suspended in sterile deionised water to a density equivalent to 0.5 McFarland
units using a densitometer (approx. 1.5  108 CFU/mL) and then diluted 1 in 15. A 1 L aliquot of each
diluted suspension was then delivered onto plates with a multipoint inoculator to give a final inoculum
of approximately 10,000 CFU/spot as recommended [41]. Selected compounds of interest were tested
without performing the 1 in 15 dilution resulting in a heavier inoculum of 150,000 CF/spot. This
allowed us to assess their ability to inhibit large inocula of commensal bacteria that might potentially
be present in clinical samples. All plates (including antimicrobial-free controls) were incubated for 22
h at 37 C. The minimum inhibitory concentration (MIC) was recorded as the lowest concentration of
test compound that resulted in complete inhibition of bacterial growth.
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4. Conclusions
This paper introduces novel antibacterial agents specifically inhibiting the growth of certain
bacteria. Such compounds can potentially be exploited to increase the selectivity and eectiveness of
the detection of clinically important pathogens by chromogenic or fluorogenic culture media.
Antibacterial agents targeting the common bacterial enzyme alanine racemase were developed and
investigated. Two 1-aminoalkyltetrazoles were synthesized as potential alanine racemase inhibitors.
All molecules were tested against a collection of clinically relevant pathogenic bacteria. As the
transportation of a single alanine unit into the cell is not provided by any bacteria, these molecules did
not inhibit the growth of any bacteria when deployed as the simple amino acid analogue.
Selected di- and tri- and succinyl oligo-peptide analogues of l-1-aminoethyltetrazole were designed
and synthesized by a novel solid phase peptide coupling method to enable the transportation of
these molecules into specially targeted bacterial cells. Many of these peptides displayed significant
antibacterial activity. Depending upon the attached amino acids, the substrates caused growth inhibition
of bacteria with dierent levels of selectivity. The selective inhibition of enterococci while not aecting
the growth of other Gram-positive cocci by l-pyroglutamyl dipeptide 14f-LL is potentially a valuable
result. The most significant example is the selective inhibition of E. coli and some Enterobacterales
by l-alanyl- 14a-LL, l-leucyl- 14h-LL and dialanyl- 14c-LLL substrates. These compounds should be
investigated in clinical applications, as they could provide a selective antibacterial ingredient in a
Salmonella selective culture medium.
In this report an important limiting factor is that very few results are presented to demonstrate
inhibition ofE. coli and growth ofSalmonella in the presence of these inhibitors, as only two representative
strains of each have been tested. However, the successful application of an analogous inhibitor,
alafosfalin, in culture media for Salmonella gives us some expectation that these new inhibitors could
demonstrate equivalent utility [42]. Further investigations are clearly warranted and these need to
include the testing of a large collection of Salmonella isolates as well as large numbers of other species
of Enterobacterales, using procedures that have previously been documented for analogous compounds
such as alafosfalin [42]. Furthermore, for any new culture medium, multicentre trials with clinical
specimens would be required, as previously described [42].
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